Jazz Pharmaceuticals (JAZZ) 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Oct. 30, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	JAZZ
Entity Registrant Name	Jazz Pharmaceuticals plc
Entity Central Index Key	1,232,524
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		61,497,753

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 998,859	$ 684,042
Accounts receivable, net of allowances	195,816	186,371
Inventories	30,018	30,037
Prepaid expenses	21,275	12,800
Deferred tax assets, net	50,006	48,440
Other current assets	18,969	21,322
Assets held for sale	0	32,833
Total current assets	1,314,943	1,015,845
Property and equipment, net	83,452	58,363
Intangible assets, net	1,270,777	1,437,435
Goodwill	669,029	702,713
Deferred tax assets, net, non-current	76,391	75,494
Deferred financing costs	24,315	33,174
Other non-current assets	25,393	15,931
Total assets	3,464,300	3,338,955
Current liabilities:
Accounts payable	29,124	25,126
Accrued liabilities	166,375	164,091
Current portion of long-term debt	117,589	9,428
Income taxes payable	16,357	7,588
Deferred tax liability, net	9,417	9,430
Deferred revenue	1,330	1,138
Total current liabilities	340,192	216,801
Deferred revenue, non-current	3,646	4,499
Long-term debt, less current portion	1,172,103	1,333,000
Deferred tax liability, net, non-current	325,216	375,054
Other non-current liabilities	$ 59,666	$ 38,393
Commitments and contingencies
Jazz Pharmaceuticals plc shareholders' equity
Ordinary shares	$ 6	$ 6
Non-voting euro deferred shares	55	55
Capital redemption reserve	471	471
Additional paid-in capital	1,534,032	1,458,005
Accumulated other comprehensive loss	(231,277)	(122,097)
Retained earnings	260,176	34,704
Total Jazz Pharmaceuticals plc shareholders’ equity	1,563,463	1,371,144
Noncontrolling interests	14	64
Total shareholders’ equity	1,563,477	1,371,208
Total liabilities and shareholders’ equity	$ 3,464,300	$ 3,338,955

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Product sales, net	$ 338,754	$ 304,407	$ 977,895	$ 838,493
Royalties and contract revenues	2,118	2,177	6,027	6,240
Total revenues	340,872	306,584	983,922	844,733
Operating expenses:
Cost of product sales (excluding amortization and impairment of intangible assets)	28,385	26,994	78,496	88,610
Selling, general and administrative	104,044	93,501	323,564	300,420
Research and development	50,784	22,423	105,798	60,622
Acquired in-process research and development	0	75,000	0	202,000
Intangible asset amortization	26,127	30,630	74,472	94,607
Impairment charges	0	0	0	32,806
Total operating expenses	209,340	248,548	582,330	779,065
Income from operations	131,532	58,036	401,592	65,668
Interest expense, net	(12,650)	(14,530)	(44,707)	(36,035)
Foreign currency gain (loss)	(977)	6,483	(646)	6,680
Loss on extinguishment and modification of debt	0	0	(16,815)	0
Income before income tax provision	117,905	49,989	339,424	36,313
Income tax provision	29,945	24,221	92,651	60,598
Net income (loss)	87,960	25,768	246,773	(24,285)
Net income (loss) attributable to noncontrolling interests, net of tax	0	2	(1)	(1,060)
Net income (loss) attributable to Jazz Pharmaceuticals plc	$ 87,960	$ 25,766	$ 246,774	$ (23,225)
Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
Basic (in dollars per share)	$ 1.43	$ 0.43	$ 4.04	$ (0.39)
Diluted (in dollars per share)	$ 1.39	$ 0.41	$ 3.91	$ (0.39)
Weighted-average ordinary shares used in per share calculation - basic (in shares)	61,435	60,305	61,145	59,457
Weighted-average ordinary shares used in per share calculation - diluted (in shares)	63,154	62,680	63,072	59,457

Condensed Consolidated Stateme4

Condensed Consolidated Statements Of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 87,960	$ 25,768	$ 246,773	$ (24,285)
Other comprehensive income (loss):
Foreign currency translation adjustments	16,779	(117,089)	(109,174)	(113,293)
Other comprehensive income (loss)	16,779	(117,089)	(109,174)	(113,293)
Total comprehensive income (loss)	104,739	(91,321)	137,599	(137,578)
Comprehensive income (loss) attributable to noncontrolling interests, net of tax	14	(8)	5	(1,067)
Comprehensive income (loss) attributable to Jazz Pharmaceuticals plc	$ 104,725	$ (91,313)	$ 137,594	$ (136,511)

Condensed Consolidated Stateme5

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net income (loss)	$ 246,773	$ (24,285)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Intangible asset amortization	74,472	94,607
Share-based compensation	67,233	50,618
Impairment charges	0	32,806
Depreciation	7,143	5,037
Acquired in-process research and development	0	202,000
Loss on disposal of property and equipment	117	0
Excess tax benefit from share-based compensation	320	(4,075)
Acquisition accounting inventory fair value step-up adjustments	0	10,477
Deferred income taxes	(25,368)	(36,246)
Provision for losses on accounts receivable and inventory	4,021	2,873
Loss on extinguishment and modification of debt	16,815	0
Amortization of debt discount and deferred financing costs	17,348	7,603
Other non-cash transactions	(3,834)	(7,382)
Changes in assets and liabilities:
Accounts receivable	(10,661)	(50,690)
Inventories	(3,595)	(10,184)
Prepaid expenses and other current assets	(5,298)	4,262
Other long-term assets	(9,555)	(5,775)
Accounts payable	4,826	(33,865)
Accrued liabilities	4,642	19,468
Income taxes payable	8,993	19,003
Deferred revenue	(659)	(918)
Contingent consideration	0	(14,900)
Other non-current liabilities	18,469	12,910
Net cash provided by operating activities	412,202	273,344
Investing activities
Net proceeds from sale of business	33,703	0
Purchases of property and equipment	(32,591)	(22,799)
Acquisitions, net of cash acquired	0	(828,676)
Acquisition of in-process research and development	0	(202,000)
Net cash provided by (used in) investing activities	1,112	(1,053,475)
Financing activities
Net proceeds from issuance of debt	898,960	1,195,366
Proceeds from employee equity incentive and purchase plans and exercise of warrants	34,025	48,452
Repayments of long-term debt	(896,363)	(7,090)
Payment of employee withholding taxes related to share-based awards	(25,402)	(17,306)
Share repurchases	(21,302)	(29,973)
Excess tax benefit from share-based compensation	(320)	4,075
Acquisition of noncontrolling interests	(60)	(136,950)
Payment of contingent consideration	0	(35,100)
Repayments under revolving credit facility	(80,000)	(300,000)
Net cash provided by (used in) financing activities	(90,462)	721,474
Effect of exchange rates on cash and cash equivalents	(8,035)	(2,807)
Net increase (decrease) in cash and cash equivalents	314,817	(61,464)
Cash and cash equivalents, at beginning of period	684,042	636,504
Cash and cash equivalents, at end of period	$ 998,859	$ 575,040

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
The Company and Summary of Significant Accounting Policies	The Company and Summary of Significant Accounting Policies Jazz Pharmaceuticals plc, a public limited company formed under the laws of Ireland, is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. In these areas, we market Xyrem ® (sodium oxybate) oral solution and Erwinaze ® (asparaginase Erwinia chrysanthemi ) in the United States, and we market Erwinase ® and Defitelio ® (defibrotide) in countries outside the United States. Our strategy is to create shareholder value by: • Growing sales of the existing products in our portfolio, including by identifying new growth opportunities; • Acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and • Pursuing focused development of a pipeline of post-discovery differentiated product candidates. Throughout this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “the registrant,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. Throughout this report, all references to “ordinary shares” refer to Jazz Pharmaceuticals plc’s ordinary shares. Basis of Presentation These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission, or SEC, for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2014 . In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015 , for any other interim period or for any future period. These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries, and intercompany transactions and balances have been eliminated. We record noncontrolling interests in our condensed consolidated financial statements which represent the ownership interest of minority shareholders in the equity of Gentium S.p.A., or Gentium. Our condensed consolidated financial statements include the results of operations of businesses we have acquired from the date of each acquisition for the applicable reporting periods. Significant Risks and Uncertainties Our financial results remain significantly influenced by sales of Xyrem. In the three and nine months ended September 30, 2015 , net product sales of Xyrem were $242.9 million and $703.4 million , respectively, which represented 71.7% and 71.9% of total net product sales, respectively. Our ability to maintain or increase sales of Xyrem in its approved indications is subject to a number of risks and uncertainties, including the potential introduction of generic competition or an alternative sodium oxybate product that competes with Xyrem; changed or increased regulatory restrictions; our manufacturing partners’ ability to obtain sufficient quota from the U.S. Drug Enforcement Administration, or DEA; any supply, manufacturing or distribution problems arising with any of our manufacturing and distribution partners, all of whom are sole source providers for us; any increase in pricing pressure from or restrictive conditions for reimbursement required by, and the availability of reimbursement from, third party payors; changes in healthcare laws and policy; continued acceptance of Xyrem by physicians and patients; changes to our label, including new safety warnings or changes to our boxed warning, that further restrict how we market and sell Xyrem; any failure of our transition to the final approved risk evaluation and mitigation strategy, or REMS, to meet the requirements of the U.S. Food and Drug Administration, or FDA; and any further operational disruptions at the central pharmacy as a result of the transition to the final approved Xyrem REMS and resulting adverse impacts on Xyrem product sales. Seven abbreviated new drug applications, or ANDAs, have been filed with the FDA by third parties seeking to market generic versions of Xyrem. We have filed lawsuits seeking to prevent the introduction of a generic version of Xyrem that would infringe our patents, and the litigation proceedings are ongoing. We cannot predict the timing or outcome of these proceedings. Although no trial date has been set in any of the ANDA suits, we anticipate that trial on some of the patents in the case against the first ANDA filer, Roxane Laboratories, Inc., or Roxane, could occur as early as the first quarter of 2016. In addition, in January 2015, certain of the ANDA filers filed petitions for inter partes review, or IPR, by the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office with respect to the validity of six patents covering the distribution system for Xyrem. In July 2015, the PTAB issued decisions instituting IPR trials with respect to these petitions, and we expect the PTAB to issue final decisions on the validity of the patents within a year of institution. In September and October 2015, certain of the ANDA filers filed petitions for IPR by the PTAB with respect to the validity of an additional patent covering the distribution system for Xyrem and with respect to the validity of one of our patents covering a method for prescribing Xyrem when it is being co-administered with divalproex sodium (also known as valproate or valproic acid). In addition, in April 2015, a hedge fund filed an IPR petition challenging the validity of one of our Xyrem distribution patents that is already the subject of one of the IPR petitions proceeding to trial before the PTAB. The PTAB issued a decision denying institution of IPR proceedings with respect to this petition. We cannot predict whether additional post-grant patent review challenges will be filed by any of the ANDA filers or any other entity, the outcome of any IPR or other proceeding, whether the PTAB will institute any petitioned IPR proceeding that has not yet been instituted, or the impact any IPR or other proceeding might have on ongoing ANDA litigation proceedings or other aspects of our Xyrem business. We expect that the approval of an ANDA that results in the launch of a generic version of Xyrem, or the approval and launch of other sodium oxybate products that compete with Xyrem, would have a material adverse effect on our business, financial condition, results of operations and growth prospects. In late August 2015, we implemented the final Xyrem REMS approved by the FDA in late February 2015. The process under which enrolled patients receive Xyrem is complex and includes multiple mandatory steps taken by the central pharmacy. The transition to the final approved REMS necessitated significant operational changes at the central pharmacy and revised documentation requirements for patients and prescribers. In the third quarter of 2015, Xyrem product sales were impacted by operational disruption and resulting delays in prescription fills and refills. As physicians and patients familiarized themselves with the new REMS process and documentation requirements, the central pharmacy experienced a significantly increased volume of calls from patients and physicians’ offices that the pharmacy was not able to timely address, resulting in a backlog of prescription fills and refills that were delayed. We have identified and are addressing with the central pharmacy to the extent feasible the processes that led to the operational delays, and to date in the fourth quarter, we have observed an improvement in key operational metrics compared to the third quarter. However, we may experience further disruptions and resulting adverse impacts on Xyrem product sales. In addition, we cannot guarantee that our implementation of the Xyrem REMS will meet FDA requirements, that the ongoing assessments that we submit in accordance with the FDA’s Xyrem REMS approval will be satisfactory to the FDA, or that the Xyrem REMS will satisfy the FDA’s expectations in its anticipated evaluation of the Xyrem REMS on an ongoing basis. Any failure to transition to the Xyrem REMS to the satisfaction of the FDA or to comply with the REMS obligations could result in enforcement action by the FDA; lead to changes in our Xyrem REMS obligations; continue to negatively affect sales of Xyrem; result in additional costs and expenses for us; and/or take a significant amount of time, any of which could materially and adversely affect our business, financial condition, results of operations and growth prospects. Further, we cannot predict whether the FDA will seek to require or ultimately require modifications to the Xyrem REMS, including with respect to the distribution system, or seek to otherwise impose or ultimately impose additional requirements to the Xyrem REMS, or the potential timing, terms or propriety thereof. Any such modifications or additional requirements could potentially make it more difficult or expensive for us to distribute Xyrem, make it easier for future generic competitors, and/or negatively affect sales of Xyrem. We may face pressure to develop a single shared REMS with potential generic competitors for Xyrem or to license or share intellectual property pertinent to the Xyrem REMS, which is the subject of multiple issued patents, or elements of the Xyrem REMS, with generic competitors. In January 2014, the FDA held an initial meeting with us and the three then-current sodium oxybate ANDA applicants to facilitate the development of a single shared REMS for sodium oxybate. In October 2015, the FDA held a telephonic meeting with us and the seven current sodium oxybate ANDA applicants to discuss the status of the development of a single shared REMS for sodium oxybate. The parties had regular interactions with respect to developing a single shared REMS prior to this meeting, and we are seeking to continue the interactions with the goal of developing a single shared REMS. We cannot predict whether, or to what extent, interactions among the parties will continue or whether we will develop a single shared REMS. If we do not develop a single shared REMS or license or share intellectual property pertinent to our Xyrem REMS with generic competitors within a time frame or on terms that the FDA considers acceptable, the FDA may assert that its waiver authority permits it to approve the ANDA of one or more generic competitors with a separate REMS that differs from our approved Xyrem REMS. We cannot predict the outcome or impact on our business of any future action that we may take with respect to the development of a single shared REMS for sodium oxybate, licensing or sharing intellectual property pertinent to our Xyrem REMS, or the FDA’s response to a request by one or more ANDA applicants for a waiver of the requirement for a single shared REMS, including in connection with a certification that the applicant had been unable to obtain a license. In addition, the Federal Trade Commission, other governmental authorities or others could claim or determine that we are using the Xyrem REMS in an anticompetitive manner (including in light of the FDA’s statement in the Xyrem REMS approval notice that the Xyrem REMS could be used in an anticompetitive manner inconsistent with applicable provisions of the Federal Food, Drug and Cosmetic Act) or have engaged in other anticompetitive practices. Obtaining and maintaining appropriate reimbursement for Xyrem in the U.S. is increasingly challenging due to, among other things, the attention being paid to healthcare cost containment and prescription drug pricing, pricing pressure from third party payors and increasingly restrictive reimbursement conditions being imposed by third party payors. In this regard, we have experienced and expect to continue to experience increasing pressure from third party payors to agree to discounts, rebates or other pricing terms for Xyrem. Any such restrictive pricing terms or additional reimbursement conditions could have a material adverse effect on our Xyrem revenues. In addition, drug pricing by pharmaceutical companies has recently come under close scrutiny, particularly with respect to companies that have increased the price of products after acquiring those products from other companies. We expect that healthcare policies and reforms intended to curb healthcare costs will continue to be proposed, which could limit the prices that we charge for our products, including Xyrem, limit our commercial opportunity and/or negatively impact revenues from sales of our products. Also, price increases on Xyrem and our other products, and negative publicity regarding pricing and price increases generally, whether with respect to our products or products distributed by other pharmaceutical companies, could negatively affect market acceptance of Xyrem and our other products. In the three and nine months ended September 30, 2015 , sales of our second largest product, Erwinaze/Erwinase (which we refer to in this report as Erwinaze unless otherwise indicated or the context otherwise requires), were $56.3 million and $152.8 million , respectively, which represented 16.6% and 15.6% of total net product sales, respectively. We seek to maintain and increase sales of Erwinaze, as well as to make Erwinaze more widely available, through ongoing sales and marketing and research and development activities. However, our ability to successfully and sustainably maintain or grow sales of Erwinaze is subject to a number of risks and uncertainties, including the limited population of patients with acute lymphoblastic leukemia, or ALL, and the incidence of hypersensitivity reactions to E. coli -derived asparaginase within that population, as well as our need to apply for and receive marketing authorizations, through the European Union’s mutual recognition procedure or otherwise, in certain additional countries so we can launch promotional efforts in those countries. Another significant challenge to our ability to maintain current sales levels and to increase sales is our need to avoid supply interruptions of Erwinaze due to capacity constraints, production delays, quality challenges or other manufacturing difficulties. We have limited inventory of Erwinaze, which puts us at significant risk of not being able to meet product demand. Erwinaze is licensed from and manufactured by a single source, which was Public Health England, or PHE, through March 31, 2015. As of April 1, 2015, the facility at which Erwinaze is manufactured was transferred to Porton BioPharma Limited, or PBL, a limited liability company that is wholly-owned by the U.K. Secretary of State for Health. We are now working with PBL on matters related to Erwinaze supply. The current manufacturing capacity for Erwinaze is nearly completely absorbed by demand for the product. As a consequence of constrained manufacturing capacity, we have had an extremely limited ability to build an excess level of product inventory that could be used to absorb disruptions to supply resulting from any quality or other issues. If we continue to be subject to capacity constraints or experience quality or other manufacturing challenges in the future, we may be unable to build a desired excess level of product inventory, and our ability to supply the market may be compromised. Although we are taking steps to improve the Erwinaze manufacturing process, if our ongoing efforts are not successful, we could experience additional Erwinaze supply interruptions in the future, which could have a material adverse effect on our sales of and revenues from Erwinaze and limit our potential future maintenance and growth of the market for this product. In addition, while we continue to work with the manufacturer of Erwinaze to evaluate potential steps to expand production capacity to increase the supply of Erwinaze over the longer term to address worldwide demand, our ability to maintain or increase sales of Erwinaze may be limited by our ability to obtain a sufficient supply of the product. In furtherance of our growth strategy, we have made a significant investment in Defitelio/defibrotide. We added the product to our portfolio as a result of our acquisition of Gentium that closed in January 2014, or the Gentium Acquisition, and secured worldwide rights to the product by acquiring rights to defibrotide in the Americas in August 2014. Our ability to realize the anticipated benefits from this investment is subject to a number of risks and uncertainties, including our ability to successfully maintain or grow sales of Defitelio in Europe, or obtain marketing approval in other countries, including the United States, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We began to launch Defitelio in certain European countries in 2014, and in 2015 we have continued to launch Defitelio in additional European countries on a rolling basis. We are in the process of making pricing and reimbursement submissions with respect to Defitelio in those European countries where Defitelio is not yet launched, including in countries where pricing and reimbursement approvals are required for launch. A key challenge to our success in maintaining or growing sales of Defitelio in Europe is our ability to obtain appropriate pricing and reimbursement approvals in those European countries where Defitelio is not yet launched. If we experience delays or unforeseen difficulties in obtaining favorable pricing and reimbursement approvals, planned launches in the affected countries would be delayed, or, if we are unable to ultimately obtain favorable pricing and reimbursement approvals in countries that represent significant markets, especially where a country’s reimbursed price influences other countries, our growth prospects in Europe could be negatively affected. We are also engaged in activities related to the potential approval of defibrotide in the United States. In September 2015, the FDA accepted for filing with priority review our new drug application, or NDA, for defibrotide for the treatment of hepatic veno-occlusive disease, or VOD, with evidence of multi-organ dysfunction following hematopoietic stem cell transplantation, or HSCT. Based on timelines established by the Prescription Drug User Fee Act, or PDUFA, we expect FDA review of the NDA to be completed by March 31, 2016. However, the FDA does not always meet the timelines established by PDUFA, and it is possible that the FDA’s review of our NDA will not be completed by the PDUFA date, in which case our plans for commercialization of defibrotide in the U.S. may be delayed. In any event, we cannot predict whether our NDA will be approved in a timely manner, if at all. It is possible that the FDA may ask an Oncologic Drugs Advisory Committee, or ODAC, which provides the FDA with independent expert advice and recommendations, to review our NDA. The ODAC may recommend against approval of our NDA, may recommend conditioning approval on our conducting one or more potentially time-consuming and costly clinical trials to provide supporting data either before approval or as a post-marketing commitment, or may recommend more narrow or restricted labeling than we have proposed. In addition, approval of our NDA is dependent on our and our supplier’s ability to obtain FDA certification of Good Manufacturing Practices in connection with the manufacturing of the defibrotide drug compound and the processing of defibrotide into finished product for the U.S. market and on the outcome of FDA inspections of clinical sites and potentially other entities involved in the development of defibrotide. In May 2015, the FDA issued a Form 483 to the entity that manufactures the defibrotide finished product that included observations related to the facility where the product is manufactured. Failure by such entity to timely remediate the observations to the FDA’s satisfaction or the discovery of issues that impact the defibrotide finished product could have an adverse impact on the potential approval of our NDA for defibrotide, including the timing thereof. We also face other challenges that could impact the anticipated value of Defitelio/defibrotide, including the limited size of the population of VOD patients who are indicated for treatment with Defitelio/defibrotide (particularly if the FDA requires more narrow or restricted labeling than we have proposed); the need to establish U.S. pricing and reimbursement support for the product in the event we are able to obtain U.S. marketing approval for defibrotide; the possibility that we may be required to conduct time-consuming and costly clinical trials as a condition of any U.S. marketing approval for the product; the lack of experience of U.S. physicians in diagnosing and treating VOD; and challenges to our ability to develop the product for additional indications. Any of these risks could have a material adverse effect on our anticipated revenue from Defitelio/defibrotide and our business, financial condition, results of operations and growth prospects. In addition to risks specifically related to Xyrem, Erwinaze and Defitelio/defibrotide, we are subject to other challenges and risks specific to our business, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including: the challenges of protecting and enhancing our intellectual property rights; delays or problems in the supply or manufacture of our products, particularly with respect to certain products as to which we maintain limited inventories, including products for which our supply demands are growing, and our dependence on single source suppliers to continue to meet our ongoing commercial demand or our requirements for clinical trial supplies; the need to obtain and maintain appropriate pricing and reimbursement for our products in an increasingly challenging environment due to, among other things, the attention being paid to healthcare cost containment and prescription drug pricing in the United States and worldwide; and the challenges of compliance with the requirements of the FDA, DEA, and non-U.S. regulatory agencies, including with respect to product labeling, requirements for distribution, obtaining sufficient DEA quotas where needed, marketing and promotional activities, adverse event reporting and product recalls or withdrawals. Other risks and uncertainties related to our ability to execute on our strategy include: the challenges of achieving and maintaining commercial success of our products, such as obtaining sustained acceptance and support of our products by patients, physicians and payors; the risks and costs associated with business combination or product or product candidate acquisition transactions, such as the challenges inherent in the integration of acquired businesses with our historic business, the increase in geographic dispersion among our centers of operation, taking on the operation of a manufacturing plant as a result of the Gentium Acquisition and the risks that we may acquire unanticipated liabilities along with acquired businesses or otherwise fail to realize the anticipated benefits (commercial or otherwise) from such transactions; the difficulty and uncertainty of pharmaceutical product development, including the timing thereof, and the uncertainty of clinical success, such as the risk that results from preclinical studies and/or early clinical trials may not be predictive of results obtained in later and larger clinical trials that we are conducting or that we plan to conduct for our product candidates; the inherent uncertainty associated with the regulatory approval process, especially as we continue to undertake increased activities and make growing investment in our product pipeline development projects; our potential inability to identify and acquire, in-license or develop additional products or product candidates to grow our business; and possible restrictions on our ability and flexibility to pursue certain future corporate development and other opportunities as a result of our substantial outstanding debt obligations. Concentrations of Risk Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet. We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of September 30, 2015 , five customers accounted for 88% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or Express Scripts, which accounted for 67% of gross accounts receivable and McKesson Corporation and its affiliates, or McKesson, which accounted for 10% of gross accounts receivable. As of December 31, 2014 , five customers accounted for 86% of gross accounts receivable, including Express Scripts, which accounted for 66% of gross accounts receivable, and IDIS Limited, which accounted for 11% of gross accounts receivable. We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Net Income (Loss) Attributable to Jazz Pharmaceuticals plc per Ordinary Share Basic net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding. Basic and diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share were computed as follows (in thousands, except per share amounts): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Numerator: Net income (loss) attributable to Jazz Pharmaceuticals plc $ 87,960 $ 25,766 $ 246,774 $ (23,225 ) Denominator: Weighted-average ordinary shares used in per share calculation - basic 61,435 60,305 61,145 59,457 Dilutive effect of employee equity incentive and purchase plans 1,719 2,288 1,927 — Dilutive effect of warrants — 87 — — Weighted-average ordinary shares used in per share calculation - diluted 63,154 62,680 63,072 59,457 Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share: Basic $ 1.43 $ 0.43 $ 4.04 $ (0.39 ) Diluted $ 1.39 $ 0.41 $ 3.91 $ (0.39 ) For the nine months ended September 30, 2014, potentially dilutive ordinary shares from employee equity incentive and purchase plans and warrants were not included in the diluted net loss attributable to Jazz Pharmaceuticals plc per ordinary share because the inclusion of such shares would have an anti-dilutive effect. Potentially dilutive ordinary shares from our employee equity incentive and purchase plans, warrants and our 1.875% exchangeable senior notes due 2021, or the 2021 Notes, are determined by applying the treasury stock method to the assumed exercise of share options and warrants, the assumed vesting of outstanding restricted stock units, or RSUs, the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP, and the assumed issuance of ordinary shares upon exchange of the 2021 Notes. The potential issue of approximately 2.9 million ordinary shares issuable upon exchange of the 2021 Notes had no effect on diluted net income attributable to Jazz Pharmaceuticals plc per ordinary share because the average price of our ordinary shares for the three and nine months ended September 30, 2015 did not exceed the effective exchange price of $199.77 per ordinary share. The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 1.875% exchangeable senior notes due 2021 2,878 1,502 2,878 506 Options to purchase ordinary shares and RSUs 1,644 883 1,517 5,475 Warrants to purchase ordinary shares — — — 618 Ordinary shares under ESPP — — — 130 Recent Accounting Pronouncements In April 2015, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2015-03, “Interest - Imputation of Interest”, or ASU No. 2015-03. ASU No. 2015-03 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability instead of as an asset. ASU No. 2015-03 does not affect the recognition and measurement guidance for debt issuance costs. In August 2015, the FASB issued ASU No. 2015-15, “Interest-Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to SEC Paragraphs Pursuant to Staff Announcements at the June 2015 EITF Meeting”, or ASU No. 2015-15 . ASU No. 2015-15 indicates that the guidance in ASU No. 2015-03 did not address presentation or subsequent measurement of debt issuance costs related to line of credit arrangements. Given the absence of authoritative guidance within ASU No. 2015-03, the SEC staff has indicated that they would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the costs ratably over the term of the line of credit arrangement, regardless of whether there are any outstanding borrowings on the line of credit arrangement. This guidance is effective for us beginning January 1, 2016 and requires retrospective application. This guidance is not

Disposition

Disposition	9 Months Ended
	Sep. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
Disposition	Disposition In March 2015, we sold certain products and the related business that we originally acquired as part of our acquisition of EUSA Pharma Inc. The purchase price for the products and related business was $34.0 million , subject to pre- and post-closing purchase price adjustments. We received approximately $33 million in cash after purchase price adjustments were made. We recognized a loss on disposal of $0.2 million in the nine months ended September 30, 2015 within selling, general and administrative expenses in our condensed consolidated statements of operations. The related assets met the assets held for sale criteria and were reclassified to assets held for sale as of December 31, 2014 . Goodwill was allocated to these assets using the relative fair value method. We have determined that the disposition of these assets did not qualify for reporting as a discontinued operation, because the sale does not represent a strategic shift that has or will have a major effect on our operations and financial results.

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement Cash and cash equivalents consisted of the following (in thousands): September 30, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cash and Cash Equivalents Cash $ 193,256 $ — $ — $ 193,256 $ 193,256 Time deposits 805,603 — — 805,603 805,603 Totals $ 998,859 $ — $ — $ 998,859 $ 998,859 December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cash and Cash Equivalents Cash $ 338,262 $ — $ — $ 338,262 $ 338,262 Time deposits 345,780 — — 345,780 345,780 Totals $ 684,042 $ — $ — $ 684,042 $ 684,042 Cash equivalents are considered available-for-sale securities. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the condensed consolidated statements of operations. The following table summarizes, by major security type, our available-for-sale securities as of September 30, 2015 and December 31, 2014 that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands): September 30, 2015 December 31, 2014 Significant Other Observable Inputs (Level 2) Total Significant Total Time deposits $ 805,603 $ 805,603 $ 345,780 $ 345,780 As of September 30, 2015 , our available-for-sale securities included time deposits which were measured at fair value using Level 2 inputs and their carrying values were approximately equal to their fair values. Level 2 inputs, obtained from various third party data providers, represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data. There were no transfers between the different levels of the fair value hierarchy in 2015 or in 2014. As of September 30, 2015 , the estimated fair value of our 2021 Notes was approximately $587 million . The fair value of the 2021 Notes was estimated using quoted market prices obtained from brokers (Level 2). The estimated fair value of our borrowings under our term loan and revolving credit facility and other borrowings were approximately equal to their respective book values based on the borrowing rates currently available for variable rate loans (Level 2). As of December 31, 2014 , assets measured at fair value on a non-recurring basis subsequent to initial recognition included assets classified as held for sale on the condensed consolidated balance sheet. The carrying amount of $32.8 million for assets held for sale was equal to estimated fair value, which was based on the sales price agreed less costs to sell, and represented a Level 3 input. We completed the sale of these assets in March 2015.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in thousands): September 30, December 31, Raw materials $ 3,437 $ 3,570 Work in process 12,587 9,870 Finished goods 13,994 16,597 Total inventories $ 30,018 $ 30,037

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The gross carrying amount of goodwill was as follows (in thousands): Balance at December 31, 2014 $ 702,713 Foreign exchange (33,684 ) Balance at September 30, 2015 $ 669,029 The gross carrying amounts and net book values of our intangible assets were as follows (in thousands): September 30, 2015 December 31, 2014 Remaining Gross Accumulated Net Book Gross Accumulated Net Book Acquired developed technologies 12.2 $ 1,350,676 $ (305,982 ) $ 1,044,694 $ 1,450,606 $ (259,889 ) $ 1,190,717 Manufacturing contracts 2.3 12,037 (5,088 ) 6,949 13,012 (3,060 ) 9,952 Trademarks — 2,891 (2,891 ) — 2,914 (2,896 ) 18 Total finite-lived intangible assets 1,365,604 (313,961 ) 1,051,643 1,466,532 (265,845 ) 1,200,687 Acquired IPR&D assets 219,134 — 219,134 236,748 — 236,748 Total intangible assets $ 1,584,738 $ (313,961 ) $ 1,270,777 $ 1,703,280 $ (265,845 ) $ 1,437,435 The decrease in the gross carrying amount of intangible assets as of September 30, 2015 compared to December 31, 2014 is primarily due to the negative impact of foreign currency translation adjustments, mainly due to the strengthening of the U.S. dollar against the euro. The assumptions and estimates used to determine future cash flows and remaining useful lives of our intangible and other long-lived assets are complex and subjective. They can be affected by various factors, including external factors, such as industry and economic trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines. Based on finite-lived intangible assets recorded as of September 30, 2015 , and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands): Year Ending December 31, Estimated Amortization Expense 2015 (remainder) $ 24,172 2016 92,510 2017 92,510 2018 89,623 2019 89,399 Thereafter 663,429 Total $ 1,051,643

Certain Balance Sheet Items

Certain Balance Sheet Items	9 Months Ended
	Sep. 30, 2015
Certain Balance Sheet Items [Abstract]
Certain Balance Sheet Items	Certain Balance Sheet Items Property and equipment consisted of the following (in thousands): September 30, December 31, Construction-in-progress $ 61,061 $ 37,145 Computer software 14,050 10,634 Computer equipment 11,266 7,670 Leasehold improvements 8,782 7,931 Machinery and equipment 5,862 6,408 Furniture and fixtures 2,339 2,220 Land and buildings 1,775 1,547 Subtotal 105,135 73,555 Less accumulated depreciation and amortization (21,683 ) (15,192 ) Property and equipment, net $ 83,452 $ 58,363 Accrued liabilities consisted of the following (in thousands): September 30, December 31, Rebates and other sales deductions $ 63,676 $ 51,899 Employee compensation and benefits 33,893 46,143 Accrued milestone payment 25,000 — Sales returns reserve 7,757 14,039 Royalties 5,340 7,964 Professional fees 3,808 3,295 Accrued interest 1,927 10,327 Accrued construction-in-progress 1,690 4,931 Other 23,284 25,493 Total accrued liabilities $ 166,375 $ 164,091

Debt

Debt	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt	Debt The following table summarizes the carrying amount of our indebtedness (in thousands): September 30, December 31, 1.875% exchangeable senior notes due 2021 $ 575,000 $ 575,000 Unamortized discount on 1.875% exchangeable senior notes due 2021 (113,108 ) (124,735 ) 1.875% exchangeable senior notes due 2021, net 461,892 450,265 Term loans 747,250 890,479 Borrowings under revolving credit facility 80,000 — Other borrowings 550 1,684 Total debt 1,289,692 1,342,428 Less current portion 117,589 9,428 Total long-term debt $ 1,172,103 $ 1,333,000 Credit Agreement On June 18, 2015, Jazz Pharmaceuticals plc, as guarantor, and certain of its wholly owned subsidiaries, as borrowers, entered into a credit agreement, which we refer to as the June 2015 credit agreement, that provides for a $750.0 million principal amount term loan, which was drawn in full at closing, and a $750.0 million revolving credit facility, of which $160.0 million was drawn at closing. We used the proceeds from initial borrowings under the June 2015 credit agreement to repay in full the $893.1 million principal amount of term loans outstanding under the credit agreement that we entered into in June 2012, as subsequently amended, which we refer to as the 2012 credit agreement, and to pay related fees and expenses. The 2012 credit agreement was terminated upon repayment of the term loans outstanding thereunder. Under the June 2015 credit agreement, the term loan matures on June 18, 2020 and the revolving credit facility terminates, and any loans outstanding thereunder become due and payable, on June 18, 2020 . Borrowings under the June 2015 credit agreement bear interest, at our option, at a rate equal to either (a) the LIBOR rate, plus an applicable margin ranging from 1.50% to 2.25% per annum, based upon our secured leverage ratio, or (b) the prime lending rate, plus an applicable margin ranging from 0.50% to 1.25% per annum, based upon our secured leverage ratio. The revolving credit facility has a commitment fee payable on the undrawn amount ranging from 0.25% to 0.35% per annum based upon our secured leverage ratio. As of September 30, 2015 , the interest rate on the term loan was 2.09% and the effective interest rate was 2.38% . As of September 30, 2015 , we had a balance outstanding of $80.0 million under the revolving credit facility and a further $1.1 million was committed for an outstanding letter of credit. As of September 30, 2015 , the interest rate on borrowings under the revolving credit facility was 1.96% . In October 2015, we repaid the remaining $80.0 million balance then outstanding under the revolving credit facility in full. Jazz Pharmaceuticals plc and certain of our wholly-owned subsidiaries are borrowers under the June 2015 credit agreement. The borrowers’ obligations under the June 2015 credit agreement, and any hedging or cash management obligations entered into with a lender, are guaranteed on a senior secured basis by Jazz Pharmaceuticals plc and certain of its subsidiaries (including the issuer of the 2021 Notes as described below) and are secured by substantially all of Jazz Pharmaceuticals plc’s, the borrowers’ and the guarantor subsidiaries’ assets. We may make voluntary prepayments of principal at any time without payment of a premium. We are required to make mandatory prepayments of the term loan (without payment of a premium) with (1) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions), (2) net cash proceeds from issuances of debt (other than certain permitted debt), and (3) casualty proceeds and condemnation awards (subject to reinvestment rights and other exceptions). Principal repayments of the term loan, which are due quarterly, will begin in December 2015 and are equal to 5.0% per annum of the original principal amount of $750.0 million during the first two years, 7.5% per annum during the third year, 10.0% per annum during the fourth year and 12.5% per annum during the fifth year, with any remaining balance payable on the maturity date. The June 2015 credit agreement contains financial covenants that require Jazz Pharmaceuticals plc and its restricted subsidiaries to (a) not exceed a maximum secured net leverage ratio or (b) not fall below a cash interest coverage ratio. We were, as of September 30, 2015 , and are currently, in compliance with these financial covenants. In connection with our entry into the June 2015 credit agreement and termination of the 2012 credit agreement, we recorded a loss on extinguishment and modification of debt of $16.8 million , which was comprised of $16.0 million related to the expensing of unamortized deferred financing costs and unamortized original issue discount associated with extinguished debt and $0.8 million related to new third party fees associated with modified debt. Exchangeable Senior Notes The 2021 Notes were issued by Jazz Investments I Limited, or the Issuer, a 100%-owned finance subsidiary of Jazz Pharmaceuticals plc. The Issuer’s obligations under the 2021 Notes are fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the 2021 Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries by dividend or loan, or any legal or economic restrictions on the ability of the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or advances. There is no assurance that in the future such restrictions will not be adopted. As of September 30, 2015 , the carrying value of the equity component of the 2021 Notes, net of equity issuance costs, was $126.9 million . Maturities Scheduled maturities with respect to our long-term debt are as follows (in thousands): Year Ending December 31, Scheduled Long-Term Debt Maturities 2015 (remainder) $ 9,397 2016 37,590 2017 42,280 2018 61,037 2019 79,792 Thereafter 1,175,454 Total $ 1,405,550 As of September 30, 2015 , we recorded the balance outstanding under our revolving credit facility of $80.0 million in current liabilities based on our intent to repay this amount in October 2015.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Indemnification In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations. We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage and the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities relating to these obligations as of September 30, 2015 and December 31, 2014 . No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations. Lease and Other Commitments We have noncancelable operating leases for our office buildings and we are obligated to make payments under noncancelable operating leases for automobiles used by our sales force. Future minimum lease payments under our noncancelable operating leases as of September 30, 2015 were as follows (in thousands): Year Ending December 31, Lease Payments 2015 (remainder) $ 2,874 2016 11,683 2017 12,556 2018 8,054 2019 7,197 Thereafter 73,296 Total $ 115,660 In January 2015, we entered into an agreement to lease office space located in Palo Alto, California in a building to be constructed by the landlord. We expect to occupy this office space by the end of 2017. The lease has a term of 12 years from the commencement date as defined in the lease agreement and we have an option to extend the term of the lease twice for a period of five years each. We are obligated to make lease payments totaling approximately $88 million over the initial term of the lease. In connection with this lease, the landlord is providing a tenant improvement allowance for the costs associated with the design, development and construction of tenant improvements for the leased facility. We are obligated to fund all costs incurred in excess of the tenant improvement allowance. The scope of the planned tenant improvements do not qualify as “normal tenant improvements” under the lease accounting guidance. Accordingly, for accounting purposes, we have concluded we are the deemed owner of the building during the construction period. As of September 30, 2015 , we recorded project construction costs of $2.7 million incurred by the landlord as construction-in-progress in property and equipment, net and a corresponding financing obligation in other non-current liabilities in our condensed consolidated balance sheets. We will increase the asset and financing obligation as additional building costs are incurred by the landlord during the construction period. In the three and nine months ended September 30, 2015 , we recorded rent expense associated with the ground lease of $0.5 million and $ 1.3 million , respectively, in our condensed consolidated statements of operations. In April 2015, we amended an existing operating sublease for office space in Palo Alto, California for additional office space and extended the term of this sublease to December 2017. As a result of the amendment, we are obligated to make additional lease payments of approximately $10 million . We also obtained an option to extend the term of the sublease twice for a period of one year each. As of September 30, 2015 , we had $25.6 million of noncancelable purchase commitments due within one year, primarily related to agreements with third party manufacturers. Legal Proceedings We are involved in legal proceedings, including the following matters: Xyrem ANDA Matters: On October 18, 2010, we received a notice of Paragraph IV Patent Certification, or Paragraph IV Certification, from Roxane that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem (sodium oxybate) oral solution. Roxane’s initial notice alleged that all five patents then listed for Xyrem in the FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” or Orange Book, on the date of the notice are invalid, unenforceable or not infringed by Roxane’s proposed generic product. On November 22, 2010, we filed a lawsuit against Roxane in response to Roxane’s initial notice in the U.S. District Court for the District of New Jersey, or the District Court, seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem that would infringe our patents. In accordance with the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act, as a result of our having filed a timely lawsuit against Roxane, FDA approval of Roxane’s ANDA was stayed for 30 months , or until April 18, 2013. That stay has expired. Additional patents covering Xyrem were issued between December 2010 and December 2012, and, after receiving Paragraph IV Certification notices from Roxane, we filed additional lawsuits against Roxane on February 4, 2011, May 2, 2011, October 26, 2012 and December 5, 2012 to include these additional patents in the litigation. All of the lawsuits filed against Roxane between 2010 and 2012 have been consolidated by the District Court into a single case, or the Roxane consolidated case, alleging that 10 of our patents covering Xyrem are or will be infringed by Roxane’s ANDA and seeking a permanent injunction to prevent Roxane from launching a generic version of Xyrem that would infringe these patents. In December 2013, the District Court permitted Roxane to amend its answer in the Roxane consolidated case to allege additional equitable defenses, and the parties were given additional time for discovery on those new defenses. In addition, in March 2014, the District Court granted our motion to bifurcate and stay the portion of the Roxane consolidated case regarding patents related to the distribution system for Xyrem. Although no trial date has been scheduled, based on the District Court’s current schedule, we anticipate that trial on the patents in the Roxane consolidated case that are not subject to the stay could occur as early as the first quarter of 2016. We do not have any estimate of a possible trial date for trial on the patents in the Roxane consolidated case that are currently subject to the stay. The actual timing of events in this litigation may be significantly earlier or later than we currently anticipate, and we cannot predict the specific timing or outcome of events in this litigation. On April 1, 2014 and January 15, 2015, we received additional notices of Paragraph IV Certification from Roxane regarding newly issued patents for Xyrem listed in the Orange Book. On February 20, 2015, we filed a new lawsuit against Roxane in the District Court, alleging that three of our patents covering Xyrem are infringed or will be infringed by Roxane’s ANDA and seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem that would infringe these patents. On April 20, 2015, Roxane moved to dismiss claims involving our patent covering a part of the Xyrem label that instructs prescribers on adjusting the dose of Xyrem when it is being co-administered with divalproex sodium (also known as valproate or valproic acid) on the grounds that this patent does not cover patentable subject matter. On October 29, 2015, the District Court administratively terminated this motion to dismiss (without prejudice) pending the outcome of IPR proceedings before the PTAB relating to the patent that was the subject of Roxane’s motion. We cannot predict the timing or outcome of events in this matter or its impact on the Roxane consolidated case. On December 10, 2012, December 12, 2012 and August 8, 2013, we received notices of Paragraph IV Certification from Amneal Pharmaceuticals, LLC, or Amneal, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On January 18, 2013 and September 12, 2013, we filed lawsuits against Amneal in the District Court, alleging that nine of our patents covering Xyrem are infringed or will be infringed by Amneal’s ANDA and seeking a permanent injunction to prevent Amneal from introducing a generic version of Xyrem that would infringe these patents. These lawsuits against Amneal were consolidated by the District Court on November 6, 2013. On November 21, 2013 and November 24, 2013, we received notices of Paragraph IV Certification from Par Pharmaceutical, Inc., or Par, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On December 27, 2013, we filed a lawsuit against Par in the District Court, alleging that 13 of our patents covering Xyrem are infringed or will be infringed by Par’s ANDA and seeking a permanent injunction to prevent Par from introducing a generic version of Xyrem that would infringe these patents. In April 2014, Amneal asked the District Court to consolidate its case with the Par case, stating that both cases would proceed on the schedule for the Par case. The District Court granted this request in May 2014. The order consolidating the cases provides that Amneal’s 30 -month stay period will be extended to coincide with the date of Par’s 30 -month stay period. As a result, FDA’s approval of both Amneal’s and Par’s ANDAs is stayed until the earlier of (i) May 20, 2016, or (ii) a District Court decision finding that the identified patents are invalid, unenforceable or not infringed. We cannot predict the timing or outcome of events in the Amneal/Par consolidated case or their impact on other ongoing proceedings with Amneal or Par as described below. On April 7, 2014 and January 19, 2015, we received additional notices of Paragraph IV Certification from Amneal regarding newly issued patents for Xyrem listed in the Orange Book. On May 20, 2014 and February 6, 2015, we filed additional lawsuits against Amneal in the District Court, alleging that four of our patents covering Xyrem are infringed or will be infringed by Amneal’s ANDA and seeking a permanent injunction to prevent Amneal from introducing a generic version of Xyrem that would infringe these patents. We cannot predict the timing or outcome of events in these matters or their impact on other ongoing proceedings with Amneal. On July 3, 2014, August 6, 2014 and November 25, 2014, we received additional notices of Paragraph IV Certification from Par regarding newly issued patents for Xyrem listed in the Orange Book. We filed additional lawsuits against Par in the District Court on August 15, 2014, October 2, 2014 and January 8, 2015, alleging that three of our patents covering Xyrem are infringed or will be infringed by Par’s ANDA and seeking a permanent injunction to prevent Par from introducing a generic version of Xyrem that would infringe these patents. We cannot predict the timing or outcome of events in these matters or their impact on other ongoing proceedings with Par. On June 4, 2014, we received a notice of Paragraph IV Certification from Ranbaxy Laboratories Limited, or Ranbaxy, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On June 6, 2014, we received a notice of an amended Paragraph IV Certification from Ranbaxy. On July 15, 2014, we filed a lawsuit against Ranbaxy in the District Court, alleging that 14 of our patents covering Xyrem are infringed or will be infringed by Ranbaxy’s ANDA and seeking a permanent injunction to prevent Ranbaxy from introducing a generic version of Xyrem that will infringe these patents. On August 20, 2014 and December 1, 2014, we received additional notices of Paragraph IV Certification from Ranbaxy regarding newly issued patents for Xyrem listed in the Orange Book. On October 2, 2014 and January 9, 2015, we filed additional lawsuits against Ranbaxy in the District Court, alleging that two of our patents covering Xyrem are infringed or will be infringed by Ranbaxy’s ANDA and seeking a permanent injunction to prevent Ranbaxy from introducing a generic version of Xyrem that would infringe these patents. We cannot predict the timing or outcome of events in these matters or their impact on other ongoing proceedings with Ranbaxy. On October 30, 2014, we received a notice of Paragraph IV Certification from Watson Laboratories, Inc., or Watson, that it has submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On December 11, 2014, we filed a lawsuit against Watson in the District Court, alleging that 15 of our patents covering Xyrem are or will be infringed by Watson’s ANDA and seeking a permanent injunction to prevent Watson from introducing a generic version of Xyrem that would infringe these patents. On March 23, 2015, Watson moved to dismiss the portion of the case based on our Orange Book-listed patents covering the distribution system for Xyrem on the grounds that these patents do not cover patentable subject matter. On November 4, 2015, the District Court administratively terminated this motion to dismiss (without prejudice) pending the outcome of IPR proceedings before the PTAB relating to the patents that were the subject of Watson’s motion. We cannot predict the timing or outcome of events in this litigation. In January 2015, Amneal, Ranbaxy and Watson proposed the consolidation of their respective cases and a consolidated schedule to the District Court, while Par sought its own proposed schedule with the District Court, notwithstanding the prior consolidation of portions of the Par and Amneal cases. In April 2015, the District Court issued an order that consolidated all then-pending lawsuits against Amneal, Par, Ranbaxy and Watson into one case, the Amneal/Par/Ranbaxy/Watson consolidated case. The schedule for the Amneal/Par/Ranbaxy/Watson consolidated case has been postponed pending resolution of a request by the defendants that the District Court limit the number of asserted claims. We cannot predict the timing or outcome of events in the Amneal/Par/Ranbaxy/Watson consolidated case or their impact on other ongoing proceedings with any ANDA filer. On March 23, 2015, March 25, 2015, March 26, 2015 and April 16, 2015, we received an additional notice of Paragraph IV Certification from each of Par, Amneal, Ranbaxy and Roxane, respectively, regarding a newly issued method of treatment patent for Xyrem listed in the Orange Book. We filed additional lawsuits against Par, Amneal and Ranbaxy in the District Court on May 7, 2015 and against Roxane on June 1, 2015, alleging that this patent is infringed or will be infringed by Par’s, Amneal’s, Ranbaxy’s and Roxane’s ANDAs and seeking a permanent injunction to prevent each of these parties from introducing a generic version of Xyrem that would infringe this patent. We cannot predict the timing or outcome of events in these matters or their impact on other ongoing proceedings with any ANDA filer. On May 14, 2015, we received an additional notice of Paragraph IV Certification from Watson regarding newly issued patents for Xyrem listed in the Orange Book. On June 26, 2015, we filed a lawsuit against Watson in the District Court, alleging that two of our patents covering Xyrem are or will be infringed by Watson’s ANDA and seeking a permanent injunction to prevent Watson from introducing a generic version of Xyrem that would infringe these patents. We cannot predict the timing or outcome of events in this matter or its impact on other ongoing proceedings with any ANDA filer. On June 8, 2015, we received a Paragraph IV Certification from Wockhardt Bio AG, or Wockhardt, that it has submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. Wockhardt’s Paragraph IV Certification alleged that 15 patents listed in the Orange Book for Xyrem are invalid, unenforceable, and/or will not be infringed by Wockhardt’s proposed generic product. On July 17, 2015, we filed a lawsuit in the District Court alleging that 17 of our patents covering Xyrem are or will be infringed by Wockhardt’s ANDA and seeking a permanent injunction to prevent Wockhardt from introducing a generic version of Xyrem that would infringe our patents. We cannot predict the timing or outcome of events in this matter or its impact on other ongoing proceedings with any ANDA filer. On July 23, 2015, we received a Paragraph IV Certification from Lupin Inc., or Lupin, that it has submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. Lupin’s Paragraph IV Certification alleged that 16 patents listed in the Orange Book for Xyrem are invalid, unenforceable, and/or will not be infringed by Lupin’s proposed generic product. On September 2, 2015, we filed a lawsuit in the District Court alleging that 18 of our patents covering Xyrem are or will be infringed by Lupin’s ANDA and seeking a permanent injunction to prevent Lupin from introducing a generic version of Xyrem that would infringe our patents. We cannot predict the timing or outcome of events in this matter or its impact on other ongoing proceedings with any ANDA filer. Also on July 23, 2015, we received an additional notice of Paragraph IV Certification from Amneal regarding a newly issued patent for Xyrem listed in the Orange Book. On September 1, 2015, we filed a lawsuit against Amneal in the District Court alleging that our patent is or will be infringed by Amneal’s ANDA and seeking a permanent injunction to prevent Amneal from introducing a generic version of Xyrem that would infringe this patent. We cannot predict the timing or outcome of events in this matter or its impact on other ongoing proceedings with any ANDA filer. On September 2, 2015, we received an additional notice of Paragraph IV Certification from Par regarding a newly issued patent for Xyrem listed in the Orange Book. On October 19, 2015, we filed a lawsuit against Par in the District Court alleging that our patent is or will be infringed by Par’s ANDA and seeking a permanent injunction to prevent Par from introducing a generic version of Xyrem that would infringe this patent. We cannot predict the timing or outcome of events in this matter or its impact on other ongoing proceedings with any ANDA filer. On October 12, 2015, we received an additional notice of Paragraph IV Certification under the ANDA filed by Ranbaxy in June 2014 from Sun Pharmaceutical Industries, Ltd., or Sun, regarding a newly issued patent for Xyrem listed in the Orange Book. Sun acquired Ranbaxy in March 2015. We expect to file a lawsuit against Sun in the District Court alleging that our patent is or will be infringed by Sun’s ANDA and seeking a permanent injunction to prevent Sun from introducing a generic version of Xyrem that would infringe this patent. We cannot predict the timing or outcome of events in this matter or its impact on other ongoing proceedings with any other ANDA filer. Xyrem Post-Grant Patent Review Matters: Between June and August 2014, petitions seeking covered business method, or CBM, post-grant patent review by the PTAB were filed by certain of the ANDA filers with respect to the validity of six of our patents related to the distribution system for Xyrem. In the fall of 2014, we filed preliminary responses to the petitions in which, among other things, we asserted that the challenged patents should not be subject to CBM review. In early 2015, the PTAB issued decisions denying institution of CBM review for all of these petitions. In January 2015, certain of the ANDA filers filed petitions for IPR by the PTAB with respect to the validity of six patents covering the distribution system for Xyrem. In July 2015, the PTAB issued decisions instituting IPR trials with respect to these petitions, and we expect the PTAB to issue final decisions on the validity of the patents within a year of institution. In April 2015, a hedge fund (acting with affiliated entities and individuals and proceeding under the name of the Coalition for Affordable Drugs III LLC) filed an IPR petition challenging the validity of one of our Xyrem distribution patents that is already the subject of one of the IPR petitions proceeding to trial before the PTAB. In October 2015, the PTAB issued a decision denying institution of IPR proceedings with respect to this petition. The PTAB’s decision declining to institute IPR is final and not appealable. In September 2015, certain of the ANDA filers filed a petition for IPR by the PTAB with respect to the validity of an additional patent covering the distribution system for Xyrem. In October 2015, certain of the ANDA filers filed petitions for IPR by the PTAB with respect to the validity of one of our patents covering a method for prescribing Xyrem when it is being co-administered with divalproex sodium (also known as valproate or valproic acid). We cannot predict whether additional post-grant patent review challenges will be filed by any of the ANDA filers or any other entity, the outcome of any IPR or other proceeding, whether the PTAB will institute any petitioned IPR proceeding that has not yet been instituted, or the impact any IPR or other proceeding might have on ongoing ANDA litigation proceedings or other aspects of our Xyrem business. FazaClo ANDA Matters: Azur Pharma Public Limited Company, or Azur Pharma (prior to the business combination between Jazz Pharmaceuticals, Inc. and Azur Pharma) received notices of Paragraph IV Certifications from three generics manufacturers, Barr Laboratories, Inc., or Barr, Novel Laboratories, Inc., or Novel, and Mylan Pharmaceuticals, Inc., or Mylan, indicating that ANDAs had been filed with the FDA requesting approval to market generic versions of FazaClo ® (clozapine, USP) LD orally disintegrating clozapine tablets. Azur Pharma and CIMA Labs Inc., or CIMA, a subsidiary of Teva Pharmaceutical Industries Limited, or Teva, our licensor and the entity whose drug-delivery technology is incorporated into FazaClo LD, filed a lawsuit in response to each certification claiming infringement based on such certification against Barr on August 21, 2008, against Novel on November 25, 2008 and against Mylan on July 23, 2010. Each case was filed in the U.S. District Court for the District of Delaware, or the Delaware Court. On July 6, 2011, CIMA, Azur Pharma and Teva, which had acquired Barr, entered into an agreement settling the patent litigation, and CIMA and Azur Pharma granted a sublicense to an affiliate of Teva of Azur Pharma’s rights to have manufactured, market and sell a generic version of both FazaClo LD and FazaClo HD, as well as an option for supply of authorized generic product. The sublicense for FazaClo LD commenced in July 2012, and the sublicense for FazaClo HD commenced in May 2015. Teva exercised its option for supply of an authorized generic product for FazaClo LD and launched the authorized generic product at the end of August 2012. Teva has also exercised its option for supply of an authorized generic product for FazaClo HD. The Novel and Mylan matters had been stayed pending reexamination of the patents in the lawsuits. In September 2013 and January 2014, reexamination certificates were issued for the two patents-in-suit, and the patentability of the claims of the patents confirmed. The Delaware Court lifted the stay of litigation in the two cases in March 2014. On December 19, 2014, we and CIMA entered into an agreement with Novel settling the patent litigation against Novel, and we along with CIMA granted Novel a patent sublicense to manufacture, market and sell its generic version of FazaClo LD and, if applicable, FazaClo HD. Novel’s permitted launch date was November 2, 2015 for FazaClo LD and will be May 1, 2017 for FazaClo HD, or earlier upon the occurrence of certain events. On July 13, 2015, we entered into an agreement with Mylan settling the patent litigation against Mylan, and we granted Mylan a patent sublicense to manufacture, market, and sell its generic versions of both FazaClo LD and FazaClo HD. Mylan’s permitted launch date was November 2, 2015 for FazaClo LD and will be May 1, 2017 for FazaClo HD, or earlier depending upon the occurrence of certain events. Cutler Matter: On October 19, 2011, Dr. Neal Cutler, one of the original owners of FazaClo, filed a complaint against Azur Pharma and one of its subsidiaries, as well as Avanir Pharmaceuticals, Inc., or Avanir, in the California Superior Court in the County of Los Angeles, or the Superior Court. The complaint alleges that Azur Pharma and its subsidiary breached certain contractual obligations. Azur Pharma acquired rights to FazaClo from Avanir in 2007. The complaint alleges that as part of the acquisition of FazaClo, Azur Pharma’s subsidiary agreed to assume certain contingent payment obligations to Dr. Cutler. The complaint further alleges that certain contingent payments are due because revenue thresholds have been achieved, entitling Dr. Cutler to a $10.5 million and an additional $25.0 million contingent payment, plus unspecified punitive damages and attorneys’ fees. In March 2012, the Superior Court granted our petition to compel arbitration of the dispute in New York and stayed the Superior Court litigation. In July 2012, the arbitrator dismissed the arbitration on the grounds that the parties’ dispute falls outside of the scope of the arbitration clause in the applicable contract. That ruling was affirmed by the California Court of Appeal in January 2014, and the case was remanded to Superior Court for discovery and trial. Trial is currently scheduled for March 2016. We cannot predict the specific timing or outcome of this litigation. From time to time we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition. Other Contingencies We have not previously submitted pricing data for two radiopharmaceutical products, Quadramet ® (samarium sm 153 lexidronam injection) and ProstaScint ® (capromab pendetide), for Medicaid and the Public Health Service’s 340B drug pricing discount program. We engaged in interactions with the Centers for Medicare and Medicaid Services, or CMS, and a trade group, the Council on Radionuclides and Radiopharmaceuticals, or CORAR, regarding the reporting of Medicaid pricing data and paying Medicaid rebates for radiopharmaceutical products. In addition to the discussions with CMS as part of CORAR, we have had separate discussions with CMS directly regarding Quadramet. We sold Quadramet to a third party in December 2013, but we retained any liabilities related to sales of the product during prior periods. Similarly, we sold ProstaScint to a third party in May 2015, but we retained any liabilities related to sales of the product during prior periods. We are currently unable to predict whether price reporting and rebates will be required for Quadramet and ProstaScint and, if so, for what period they will be required. The initiation of any reporting of Medicaid pricing data for Quadramet or ProstaScint could result in retroactive 340B ceiling price liability for these two products. We are currently unable to reasonably estimate an amount or range of a potential contingent loss. Any material liability resulting from radiopharmaceutical price reporting would negatively impact our financial results.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders’ Equity The following tables present a reconciliation of our beginning and ending balances in shareholders’ equity for the nine months ended September 30, 2015 and 2014, respectively (in thousands): Attributable to: Jazz Pharmaceuticals plc Noncontrolling interests Total Shareholders' Equity Shareholders' equity at January 1, 2015 $ 1,371,144 $ 64 $ 1,371,208 Acquisition of noncontrolling interests (5 ) (55 ) (60 ) Issuance of ordinary shares in conjunction with employee equity incentive and purchase plans 34,025 — 34,025 Employee withholding taxes related to share-based awards (25,402 ) — (25,402 ) Share-based compensation 67,729 — 67,729 Tax benefit from employee share options (320 ) — (320 ) Shares repurchased (21,302 ) — (21,302 ) Other comprehensive income (loss) (109,180 ) 6 (109,174 ) Net income (loss) 246,774 (1 ) 246,773 Shareholders' equity at September 30, 2015 $ 1,563,463 $ 14 $ 1,563,477 Attributable to: Jazz Pharmaceuticals plc Noncontrolling interests Total Shareholders' Equity Shareholders' equity at January 1, 2014 $ 1,295,534 $ — $ 1,295,534 Noncontrolling interests from the Gentium Acquisition — 136,578 136,578 Acquisition of noncontrolling interests (1,529 ) (135,421 ) (136,950 ) Issuance of 1.875% exchangeable senior notes due 2021 126,862 — 126,862 Issuance of ordinary shares in conjunction with employee equity incentive and purchase plans and warrant exercises 48,452 — 48,452 Employee withholding taxes related to share-based awards (17,306 ) — (17,306 ) Share-based compensation 50,919 — 50,919 Tax benefit from employee share options 4,075 — 4,075 Shares repurchased (29,973 ) (29,973 ) Other comprehensive loss (113,286 ) (7 ) (113,293 ) Net loss (23,225 ) (1,060 ) (24,285 ) Shareholders' equity at September 30, 2014 $ 1,340,523 $ 90 $ 1,340,613 Share Repurchase Programs In May 2013, our board of directors authorized a share repurchase program pursuant to which we were authorized to repurchase a number of ordinary shares having an aggregate repurchase price of up to $200 million , exclusive of any brokerage commissions. In the nine months ended September 30, 2015 , we spent a total of $21.3 million to purchase 0.1 million of our ordinary shares under the share repurchase program at an average total purchase price, including commissions, of $172.43 per share. All ordinary shares repurchased by us were canceled. We completed this share repurchase program in August 2015 by repurchasing all $200 million of ordinary shares authorized to be repurchased. On November 5, 2015, our board of directors authorized a new share repurchase program pursuant to which we are authorized to repurchase a number of ordinary shares having an aggregate purchase price of up to $300 million , exclusive of any brokerage commissions. Under this share repurchase program, which has no expiration date, we may repurchase ordinary shares from time to time on the open market. The timing and amount of repurchases will be at management’s discretion and will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the June 2015 credit agreement, corporate and regulatory requirements and market conditions. The share repurchase program may be modified, suspended or discontinued at any time without prior notice. Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss attributable to Jazz Pharmaceuticals plc as of September 30, 2015 and December 31, 2014 were as follows (in thousands): Foreign Total Balance at December 31, 2014 $ (122,097 ) $ (122,097 ) Other comprehensive loss (109,180 ) (109,180 ) Balance at September 30, 2015 $ (231,277 ) $ (231,277 ) During the nine months ended September 30, 2015 , other comprehensive loss reflects foreign currency translation adjustments, primarily due to the strengthening of the U.S. dollar against the euro.

Segment and Other Information

Segment and Other Information	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment and Other Information	Segment and Other Information Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the development and commercialization of meaningful pharmaceutical products that address unmet medical needs. The following table presents a summary of total revenues (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Xyrem ® (sodium oxybate) oral solution $ 242,899 $ 204,337 $ 703,435 $ 556,081 Erwinaze ® /Erwinase ® (asparaginase Erwinia chrysanthemi ) 56,317 52,121 152,821 146,910 Defitelio ® (defibrotide)/defibrotide 19,639 18,892 52,259 51,345 Prialt ® (ziconotide) intrathecal infusion 6,042 6,282 19,944 16,422 Psychiatry 9,910 10,833 28,375 32,431 Other 3,947 11,942 21,061 35,304 Product sales, net 338,754 304,407 977,895 838,493 Royalties and contract revenues 2,118 2,177 6,027 6,240 Total revenues $ 340,872 $ 306,584 $ 983,922 $ 844,733 The following table presents a summary of total revenues attributed to geographic sources (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 United States $ 305,585 $ 264,719 $ 877,397 $ 727,200 Europe 26,076 32,578 82,837 87,608 All other 9,211 9,287 23,688 29,925 Total revenues $ 340,872 $ 306,584 $ 983,922 $ 844,733 The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Express Scripts 71 % 67 % 71 % 66 % McKesson 14 % 1 % 5 % 5 % Accredo Health Group, Inc. — % 14 % 8 % 14 % At the end of the second quarter of 2015, we transitioned the U.S. distribution of Erwinaze from Accredo Health Group, Inc. to McKesson. The following table presents total long-lived assets, consisting of property and equipment, by location (in thousands): September 30, December 31, Ireland $ 60,447 $ 37,775 United States 12,255 9,795 Italy 8,424 8,462 Other 2,326 2,331 Total long-lived assets $ 83,452 $ 58,363

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Selling, general and administrative $ 19,542 $ 14,834 $ 54,843 $ 40,051 Research and development 2,786 3,177 10,137 8,862 Cost of product sales 786 240 2,253 1,705 Total share-based compensation expense, pre-tax 23,114 18,251 67,233 50,618 Tax benefit from share-based compensation expense (6,658 ) (5,469 ) (19,722 ) (15,171 ) Total share-based compensation expense, net of tax $ 16,456 $ 12,782 $ 47,511 $ 35,447 Share Options The table below shows the number of shares underlying options granted to purchase our ordinary shares, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Shares underlying options granted (in thousands) 106 135 1,056 942 Grant date fair value $ 60.34 $ 51.73 $ 57.85 $ 60.40 Black-Scholes option pricing model assumption information: Volatility 40 % 42 % 39 % 45 % Expected term (years) 4.2 4.3 4.2 4.3 Range of risk-free rates 1.3-1.4% 1.3-1.4% 1.1-1.4% 1.1-1.4% Expected dividend yield — % — % — % — % Restricted Stock Units The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted: Three Months Ended Nine Months Ended 2015 2014 2015 2014 RSUs granted (in thousands) 40 68 406 459 Grant date fair value $ 179.10 $ 145.58 $ 175.22 $ 160.00 The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares on that date. The fair value of RSUs is expensed ratably over the vesting period of four years . As of September 30, 2015 , compensation cost not yet recognized related to unvested share options and RSUs was $83.4 million and $93.8 million , respectively, which is expected to be recognized over a weighted-average period of 2.5 years and 2.3 years, respectively.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the fourth quarter of 2014, we incurred severance costs for terminated employees in connection with our decision to discontinue sales representative-led promotion of our psychiatry products starting in 2015. In addition, we initiated a restructuring plan related to the consolidation of our U.K. office locations and incurred costs of severance for terminated employees and facility closure costs in connection with this plan. The one-time termination benefits were recorded over the remaining service period where employees were required to stay through their termination date to receive the benefits. We recorded costs related to these one-time termination benefits of $0.4 million in the nine months ended September 30, 2015 within selling, general and administrative expenses in our condensed consolidated statements of operations. Facility closure costs of $0.2 million incurred in the nine months ended September 30, 2015 were recorded within selling, general and administrative expenses in our condensed consolidated statements of operations. As of September 30, 2015 , we had incurred total termination benefit and facility closure costs of $2.2 million and $0.3 million , respectively, in connection with these plans. We do not expect to incur additional termination benefit or facility closure costs in connection with these plans. The following table summarizes the amounts related to restructuring through September 30, 2015 (in thousands): Termination Benefits Facility Closure Costs Total Balance at December 31, 2014 $ 1,823 $ 118 $ 1,941 Costs incurred during the period 381 172 553 Cash payments (2,204 ) (290 ) (2,494 ) Balance at September 30, 2015 $ — $ — $ — The balance as of December 31, 2014 was included within accrued liabilities in our condensed consolidated balance sheets.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our income tax provision for the three and nine months ended September 30, 2015 was $29.9 million and $92.7 million , respectively, compared to $24.2 million and $60.6 million for the same periods in 2014. Our effective tax rates for the three and nine months ended September 30, 2015 were 25.4% and 27.3% , respectively. After adjusting the income before income tax provision for the three months ended September 30, 2014 by excluding an upfront payment of $75.0 million for rights to defibrotide in the Americas, the effective tax rate on the resulting income before income tax provision for the three months ended September 30, 2014 was 19.4% . After adjusting the loss before income tax provision for the nine months ended September 30, 2014 by excluding upfront and milestone payments of $202.0 million for rights to JZP-110 and to defibrotide in the Americas, which were acquired by our subsidiary in a non-taxable jurisdiction, the effective tax rate on the resulting income before income tax provision for the nine months ended September 30, 2014 was 25.4% . The increase in the effective tax rate for the three months ended September 30, 2015 compared to the same period in 2014 was primarily due to the impact of changes in U.S. state valuation allowances during 2014, partially offset by changes in income mix among the various jurisdictions in which we operate, increased originating tax credits and increased deductions available in relation to subsidiary equity. The increase in the effective tax rate for the nine months ended September 30, 2015 compared to the same period in 2014 was primarily due to the impact of impairments of intangible assets and changes in U.S. state valuation allowances during 2014, partially offset by changes in income mix among the various jurisdictions in which we operate, increased originating tax credits and increased deductions available in relation to subsidiary equity. The effective tax rates for the three and nine months ended September 30, 2015 were higher than the Irish statutory rate of 12.5% primarily due to income taxable at a rate higher than the Irish statutory rate, uncertain tax positions, and various expenses not deductible for tax purposes, partially offset by originating tax credits and deductions available in relation to subsidiary equity. We do not provide for Irish income taxes on undistributed earnings of our foreign operations that are intended to be indefinitely reinvested in our foreign subsidiaries. Our deferred tax assets are comprised primarily of U.S. federal and state net operating loss carryforwards and tax credit carryforwards, foreign net operating loss carryforwards and other temporary differences. We maintain a valuation allowance against certain U.S. state and foreign deferred tax assets. Each reporting period, we evaluate the need for a valuation allowance on our deferred tax assets by jurisdiction and adjust our estimates as more information becomes available. We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. As a result, we have established a liability for certain tax benefits which we judge may not be sustained upon examination. Our most significant tax jurisdictions are Ireland, the United States (both at the federal level and in various state jurisdictions), Italy and France. Because of our net operating loss carryforwards and tax credit carryforwards, substantially all of our tax years remain open to federal, state, and foreign tax examination. Certain of our subsidiaries are currently under examination by the French tax authorities for fiscal years 2012 and 2013 and by Italian tax authorities for fiscal year 2012. We do not anticipate that the amount of our existing liability for unrecognized tax benefits will significantly change within the next 12 months.

The Company and Summary of Si19

The Company and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission, or SEC, for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2014 . In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015 , for any other interim period or for any future period. These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries, and intercompany transactions and balances have been eliminated. We record noncontrolling interests in our condensed consolidated financial statements which represent the ownership interest of minority shareholders in the equity of Gentium S.p.A., or Gentium. Our condensed consolidated financial statements include the results of operations of businesses we have acquired from the date of each acquisition for the applicable reporting periods.
Significant Risks and Uncertainties	Significant Risks and Uncertainties Our financial results remain significantly influenced by sales of Xyrem. In the three and nine months ended September 30, 2015 , net product sales of Xyrem were $242.9 million and $703.4 million , respectively, which represented 71.7% and 71.9% of total net product sales, respectively. Our ability to maintain or increase sales of Xyrem in its approved indications is subject to a number of risks and uncertainties, including the potential introduction of generic competition or an alternative sodium oxybate product that competes with Xyrem; changed or increased regulatory restrictions; our manufacturing partners’ ability to obtain sufficient quota from the U.S. Drug Enforcement Administration, or DEA; any supply, manufacturing or distribution problems arising with any of our manufacturing and distribution partners, all of whom are sole source providers for us; any increase in pricing pressure from or restrictive conditions for reimbursement required by, and the availability of reimbursement from, third party payors; changes in healthcare laws and policy; continued acceptance of Xyrem by physicians and patients; changes to our label, including new safety warnings or changes to our boxed warning, that further restrict how we market and sell Xyrem; any failure of our transition to the final approved risk evaluation and mitigation strategy, or REMS, to meet the requirements of the U.S. Food and Drug Administration, or FDA; and any further operational disruptions at the central pharmacy as a result of the transition to the final approved Xyrem REMS and resulting adverse impacts on Xyrem product sales. Seven abbreviated new drug applications, or ANDAs, have been filed with the FDA by third parties seeking to market generic versions of Xyrem. We have filed lawsuits seeking to prevent the introduction of a generic version of Xyrem that would infringe our patents, and the litigation proceedings are ongoing. We cannot predict the timing or outcome of these proceedings. Although no trial date has been set in any of the ANDA suits, we anticipate that trial on some of the patents in the case against the first ANDA filer, Roxane Laboratories, Inc., or Roxane, could occur as early as the first quarter of 2016. In addition, in January 2015, certain of the ANDA filers filed petitions for inter partes review, or IPR, by the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office with respect to the validity of six patents covering the distribution system for Xyrem. In July 2015, the PTAB issued decisions instituting IPR trials with respect to these petitions, and we expect the PTAB to issue final decisions on the validity of the patents within a year of institution. In September and October 2015, certain of the ANDA filers filed petitions for IPR by the PTAB with respect to the validity of an additional patent covering the distribution system for Xyrem and with respect to the validity of one of our patents covering a method for prescribing Xyrem when it is being co-administered with divalproex sodium (also known as valproate or valproic acid). In addition, in April 2015, a hedge fund filed an IPR petition challenging the validity of one of our Xyrem distribution patents that is already the subject of one of the IPR petitions proceeding to trial before the PTAB. The PTAB issued a decision denying institution of IPR proceedings with respect to this petition. We cannot predict whether additional post-grant patent review challenges will be filed by any of the ANDA filers or any other entity, the outcome of any IPR or other proceeding, whether the PTAB will institute any petitioned IPR proceeding that has not yet been instituted, or the impact any IPR or other proceeding might have on ongoing ANDA litigation proceedings or other aspects of our Xyrem business. We expect that the approval of an ANDA that results in the launch of a generic version of Xyrem, or the approval and launch of other sodium oxybate products that compete with Xyrem, would have a material adverse effect on our business, financial condition, results of operations and growth prospects. In late August 2015, we implemented the final Xyrem REMS approved by the FDA in late February 2015. The process under which enrolled patients receive Xyrem is complex and includes multiple mandatory steps taken by the central pharmacy. The transition to the final approved REMS necessitated significant operational changes at the central pharmacy and revised documentation requirements for patients and prescribers. In the third quarter of 2015, Xyrem product sales were impacted by operational disruption and resulting delays in prescription fills and refills. As physicians and patients familiarized themselves with the new REMS process and documentation requirements, the central pharmacy experienced a significantly increased volume of calls from patients and physicians’ offices that the pharmacy was not able to timely address, resulting in a backlog of prescription fills and refills that were delayed. We have identified and are addressing with the central pharmacy to the extent feasible the processes that led to the operational delays, and to date in the fourth quarter, we have observed an improvement in key operational metrics compared to the third quarter. However, we may experience further disruptions and resulting adverse impacts on Xyrem product sales. In addition, we cannot guarantee that our implementation of the Xyrem REMS will meet FDA requirements, that the ongoing assessments that we submit in accordance with the FDA’s Xyrem REMS approval will be satisfactory to the FDA, or that the Xyrem REMS will satisfy the FDA’s expectations in its anticipated evaluation of the Xyrem REMS on an ongoing basis. Any failure to transition to the Xyrem REMS to the satisfaction of the FDA or to comply with the REMS obligations could result in enforcement action by the FDA; lead to changes in our Xyrem REMS obligations; continue to negatively affect sales of Xyrem; result in additional costs and expenses for us; and/or take a significant amount of time, any of which could materially and adversely affect our business, financial condition, results of operations and growth prospects. Further, we cannot predict whether the FDA will seek to require or ultimately require modifications to the Xyrem REMS, including with respect to the distribution system, or seek to otherwise impose or ultimately impose additional requirements to the Xyrem REMS, or the potential timing, terms or propriety thereof. Any such modifications or additional requirements could potentially make it more difficult or expensive for us to distribute Xyrem, make it easier for future generic competitors, and/or negatively affect sales of Xyrem. We may face pressure to develop a single shared REMS with potential generic competitors for Xyrem or to license or share intellectual property pertinent to the Xyrem REMS, which is the subject of multiple issued patents, or elements of the Xyrem REMS, with generic competitors. In January 2014, the FDA held an initial meeting with us and the three then-current sodium oxybate ANDA applicants to facilitate the development of a single shared REMS for sodium oxybate. In October 2015, the FDA held a telephonic meeting with us and the seven current sodium oxybate ANDA applicants to discuss the status of the development of a single shared REMS for sodium oxybate. The parties had regular interactions with respect to developing a single shared REMS prior to this meeting, and we are seeking to continue the interactions with the goal of developing a single shared REMS. We cannot predict whether, or to what extent, interactions among the parties will continue or whether we will develop a single shared REMS. If we do not develop a single shared REMS or license or share intellectual property pertinent to our Xyrem REMS with generic competitors within a time frame or on terms that the FDA considers acceptable, the FDA may assert that its waiver authority permits it to approve the ANDA of one or more generic competitors with a separate REMS that differs from our approved Xyrem REMS. We cannot predict the outcome or impact on our business of any future action that we may take with respect to the development of a single shared REMS for sodium oxybate, licensing or sharing intellectual property pertinent to our Xyrem REMS, or the FDA’s response to a request by one or more ANDA applicants for a waiver of the requirement for a single shared REMS, including in connection with a certification that the applicant had been unable to obtain a license. In addition, the Federal Trade Commission, other governmental authorities or others could claim or determine that we are using the Xyrem REMS in an anticompetitive manner (including in light of the FDA’s statement in the Xyrem REMS approval notice that the Xyrem REMS could be used in an anticompetitive manner inconsistent with applicable provisions of the Federal Food, Drug and Cosmetic Act) or have engaged in other anticompetitive practices. Obtaining and maintaining appropriate reimbursement for Xyrem in the U.S. is increasingly challenging due to, among other things, the attention being paid to healthcare cost containment and prescription drug pricing, pricing pressure from third party payors and increasingly restrictive reimbursement conditions being imposed by third party payors. In this regard, we have experienced and expect to continue to experience increasing pressure from third party payors to agree to discounts, rebates or other pricing terms for Xyrem. Any such restrictive pricing terms or additional reimbursement conditions could have a material adverse effect on our Xyrem revenues. In addition, drug pricing by pharmaceutical companies has recently come under close scrutiny, particularly with respect to companies that have increased the price of products after acquiring those products from other companies. We expect that healthcare policies and reforms intended to curb healthcare costs will continue to be proposed, which could limit the prices that we charge for our products, including Xyrem, limit our commercial opportunity and/or negatively impact revenues from sales of our products. Also, price increases on Xyrem and our other products, and negative publicity regarding pricing and price increases generally, whether with respect to our products or products distributed by other pharmaceutical companies, could negatively affect market acceptance of Xyrem and our other products. In the three and nine months ended September 30, 2015 , sales of our second largest product, Erwinaze/Erwinase (which we refer to in this report as Erwinaze unless otherwise indicated or the context otherwise requires), were $56.3 million and $152.8 million , respectively, which represented 16.6% and 15.6% of total net product sales, respectively. We seek to maintain and increase sales of Erwinaze, as well as to make Erwinaze more widely available, through ongoing sales and marketing and research and development activities. However, our ability to successfully and sustainably maintain or grow sales of Erwinaze is subject to a number of risks and uncertainties, including the limited population of patients with acute lymphoblastic leukemia, or ALL, and the incidence of hypersensitivity reactions to E. coli -derived asparaginase within that population, as well as our need to apply for and receive marketing authorizations, through the European Union’s mutual recognition procedure or otherwise, in certain additional countries so we can launch promotional efforts in those countries. Another significant challenge to our ability to maintain current sales levels and to increase sales is our need to avoid supply interruptions of Erwinaze due to capacity constraints, production delays, quality challenges or other manufacturing difficulties. We have limited inventory of Erwinaze, which puts us at significant risk of not being able to meet product demand. Erwinaze is licensed from and manufactured by a single source, which was Public Health England, or PHE, through March 31, 2015. As of April 1, 2015, the facility at which Erwinaze is manufactured was transferred to Porton BioPharma Limited, or PBL, a limited liability company that is wholly-owned by the U.K. Secretary of State for Health. We are now working with PBL on matters related to Erwinaze supply. The current manufacturing capacity for Erwinaze is nearly completely absorbed by demand for the product. As a consequence of constrained manufacturing capacity, we have had an extremely limited ability to build an excess level of product inventory that could be used to absorb disruptions to supply resulting from any quality or other issues. If we continue to be subject to capacity constraints or experience quality or other manufacturing challenges in the future, we may be unable to build a desired excess level of product inventory, and our ability to supply the market may be compromised. Although we are taking steps to improve the Erwinaze manufacturing process, if our ongoing efforts are not successful, we could experience additional Erwinaze supply interruptions in the future, which could have a material adverse effect on our sales of and revenues from Erwinaze and limit our potential future maintenance and growth of the market for this product. In addition, while we continue to work with the manufacturer of Erwinaze to evaluate potential steps to expand production capacity to increase the supply of Erwinaze over the longer term to address worldwide demand, our ability to maintain or increase sales of Erwinaze may be limited by our ability to obtain a sufficient supply of the product. In furtherance of our growth strategy, we have made a significant investment in Defitelio/defibrotide. We added the product to our portfolio as a result of our acquisition of Gentium that closed in January 2014, or the Gentium Acquisition, and secured worldwide rights to the product by acquiring rights to defibrotide in the Americas in August 2014. Our ability to realize the anticipated benefits from this investment is subject to a number of risks and uncertainties, including our ability to successfully maintain or grow sales of Defitelio in Europe, or obtain marketing approval in other countries, including the United States, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We began to launch Defitelio in certain European countries in 2014, and in 2015 we have continued to launch Defitelio in additional European countries on a rolling basis. We are in the process of making pricing and reimbursement submissions with respect to Defitelio in those European countries where Defitelio is not yet launched, including in countries where pricing and reimbursement approvals are required for launch. A key challenge to our success in maintaining or growing sales of Defitelio in Europe is our ability to obtain appropriate pricing and reimbursement approvals in those European countries where Defitelio is not yet launched. If we experience delays or unforeseen difficulties in obtaining favorable pricing and reimbursement approvals, planned launches in the affected countries would be delayed, or, if we are unable to ultimately obtain favorable pricing and reimbursement approvals in countries that represent significant markets, especially where a country’s reimbursed price influences other countries, our growth prospects in Europe could be negatively affected. We are also engaged in activities related to the potential approval of defibrotide in the United States. In September 2015, the FDA accepted for filing with priority review our new drug application, or NDA, for defibrotide for the treatment of hepatic veno-occlusive disease, or VOD, with evidence of multi-organ dysfunction following hematopoietic stem cell transplantation, or HSCT. Based on timelines established by the Prescription Drug User Fee Act, or PDUFA, we expect FDA review of the NDA to be completed by March 31, 2016. However, the FDA does not always meet the timelines established by PDUFA, and it is possible that the FDA’s review of our NDA will not be completed by the PDUFA date, in which case our plans for commercialization of defibrotide in the U.S. may be delayed. In any event, we cannot predict whether our NDA will be approved in a timely manner, if at all. It is possible that the FDA may ask an Oncologic Drugs Advisory Committee, or ODAC, which provides the FDA with independent expert advice and recommendations, to review our NDA. The ODAC may recommend against approval of our NDA, may recommend conditioning approval on our conducting one or more potentially time-consuming and costly clinical trials to provide supporting data either before approval or as a post-marketing commitment, or may recommend more narrow or restricted labeling than we have proposed. In addition, approval of our NDA is dependent on our and our supplier’s ability to obtain FDA certification of Good Manufacturing Practices in connection with the manufacturing of the defibrotide drug compound and the processing of defibrotide into finished product for the U.S. market and on the outcome of FDA inspections of clinical sites and potentially other entities involved in the development of defibrotide. In May 2015, the FDA issued a Form 483 to the entity that manufactures the defibrotide finished product that included observations related to the facility where the product is manufactured. Failure by such entity to timely remediate the observations to the FDA’s satisfaction or the discovery of issues that impact the defibrotide finished product could have an adverse impact on the potential approval of our NDA for defibrotide, including the timing thereof. We also face other challenges that could impact the anticipated value of Defitelio/defibrotide, including the limited size of the population of VOD patients who are indicated for treatment with Defitelio/defibrotide (particularly if the FDA requires more narrow or restricted labeling than we have proposed); the need to establish U.S. pricing and reimbursement support for the product in the event we are able to obtain U.S. marketing approval for defibrotide; the possibility that we may be required to conduct time-consuming and costly clinical trials as a condition of any U.S. marketing approval for the product; the lack of experience of U.S. physicians in diagnosing and treating VOD; and challenges to our ability to develop the product for additional indications. Any of these risks could have a material adverse effect on our anticipated revenue from Defitelio/defibrotide and our business, financial condition, results of operations and growth prospects. In addition to risks specifically related to Xyrem, Erwinaze and Defitelio/defibrotide, we are subject to other challenges and risks specific to our business, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including: the challenges of protecting and enhancing our intellectual property rights; delays or problems in the supply or manufacture of our products, particularly with respect to certain products as to which we maintain limited inventories, including products for which our supply demands are growing, and our dependence on single source suppliers to continue to meet our ongoing commercial demand or our requirements for clinical trial supplies; the need to obtain and maintain appropriate pricing and reimbursement for our products in an increasingly challenging environment due to, among other things, the attention being paid to healthcare cost containment and prescription drug pricing in the United States and worldwide; and the challenges of compliance with the requirements of the FDA, DEA, and non-U.S. regulatory agencies, including with respect to product labeling, requirements for distribution, obtaining sufficient DEA quotas where needed, marketing and promotional activities, adverse event reporting and product recalls or withdrawals. Other risks and uncertainties related to our ability to execute on our strategy include: the challenges of achieving and maintaining commercial success of our products, such as obtaining sustained acceptance and support of our products by patients, physicians and payors; the risks and costs associated with business combination or product or product candidate acquisition transactions, such as the challenges inherent in the integration of acquired businesses with our historic business, the increase in geographic dispersion among our centers of operation, taking on the operation of a manufacturing plant as a result of the Gentium Acquisition and the risks that we may acquire unanticipated liabilities along with acquired businesses or otherwise fail to realize the anticipated benefits (commercial or otherwise) from such transactions; the difficulty and uncertainty of pharmaceutical product development, including the timing thereof, and the uncertainty of clinical success, such as the risk that results from preclinical studies and/or early clinical trials may not be predictive of results obtained in later and larger clinical trials that we are conducting or that we plan to conduct for our product candidates; the inherent uncertainty associated with the regulatory approval process, especially as we continue to undertake increased activities and make growing investment in our product pipeline development projects; our potential inability to identify and acquire, in-license or develop additional products or product candidates to grow our business; and possible restrictions on our ability and flexibility to pursue certain future corporate development and other opportunities as a result of our substantial outstanding debt obligations.
Concentrations of Risk	Concentrations of Risk Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet. We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of September 30, 2015 , five customers accounted for 88% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or Express Scripts, which accounted for 67% of gross accounts receivable and McKesson Corporation and its affiliates, or McKesson, which accounted for 10% of gross accounts receivable. As of December 31, 2014 , five customers accounted for 86% of gross accounts receivable, including Express Scripts, which accounted for 66% of gross accounts receivable, and IDIS Limited, which accounted for 11% of gross accounts receivable. We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.
Net Income (Loss) Attributable to Jazz Pharmaceuticals plc per Ordinary Share	Net Income (Loss) Attributable to Jazz Pharmaceuticals plc per Ordinary Share Basic net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding. Basic and diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share were computed as follows (in thousands, except per share amounts): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Numerator: Net income (loss) attributable to Jazz Pharmaceuticals plc $ 87,960 $ 25,766 $ 246,774 $ (23,225 ) Denominator: Weighted-average ordinary shares used in per share calculation - basic 61,435 60,305 61,145 59,457 Dilutive effect of employee equity incentive and purchase plans 1,719 2,288 1,927 — Dilutive effect of warrants — 87 — — Weighted-average ordinary shares used in per share calculation - diluted 63,154 62,680 63,072 59,457 Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share: Basic $ 1.43 $ 0.43 $ 4.04 $ (0.39 ) Diluted $ 1.39 $ 0.41 $ 3.91 $ (0.39 ) For the nine months ended September 30, 2014, potentially dilutive ordinary shares from employee equity incentive and purchase plans and warrants were not included in the diluted net loss attributable to Jazz Pharmaceuticals plc per ordinary share because the inclusion of such shares would have an anti-dilutive effect. Potentially dilutive ordinary shares from our employee equity incentive and purchase plans, warrants and our 1.875% exchangeable senior notes due 2021, or the 2021 Notes, are determined by applying the treasury stock method to the assumed exercise of share options and warrants, the assumed vesting of outstanding restricted stock units, or RSUs, the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP, and the assumed issuance of ordinary shares upon exchange of the 2021 Notes. The potential issue of approximately 2.9 million ordinary shares issuable upon exchange of the 2021 Notes had no effect on diluted net income attributable to Jazz Pharmaceuticals plc per ordinary share because the average price of our ordinary shares for the three and nine months ended September 30, 2015 did not exceed the effective exchange price of $199.77 per ordinary share. The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 1.875% exchangeable senior notes due 2021 2,878 1,502 2,878 506 Options to purchase ordinary shares and RSUs 1,644 883 1,517 5,475 Warrants to purchase ordinary shares — — — 618 Ordinary shares under ESPP — — — 130
Recent Accounting Pronouncements	Recent Accounting Pronouncements In April 2015, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2015-03, “Interest - Imputation of Interest”, or ASU No. 2015-03. ASU No. 2015-03 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability instead of as an asset. ASU No. 2015-03 does not affect the recognition and measurement guidance for debt issuance costs. In August 2015, the FASB issued ASU No. 2015-15, “Interest-Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to SEC Paragraphs Pursuant to Staff Announcements at the June 2015 EITF Meeting”, or ASU No. 2015-15 . ASU No. 2015-15 indicates that the guidance in ASU No. 2015-03 did not address presentation or subsequent measurement of debt issuance costs related to line of credit arrangements. Given the absence of authoritative guidance within ASU No. 2015-03, the SEC staff has indicated that they would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the costs ratably over the term of the line of credit arrangement, regardless of whether there are any outstanding borrowings on the line of credit arrangement. This guidance is effective for us beginning January 1, 2016 and requires retrospective application. This guidance is not expected to have a material impact on our consolidated balance sheets or related disclosures. In April 2015, the FASB issued ASU No. 2015-05, “Intangibles-Goodwill and Other-Internal-Use Software”, or ASU No. 2015-05. ASU No. 2015-05 provides guidance on whether a cloud computing arrangement contains a software license to be accounted for as internal-use software to assist in the evaluation of the accounting for fees paid by a customer in the arrangement. ASU No. 2015-05 will be effective for us beginning January 1, 2016 and may be applied either prospectively to new cloud computing arrangements or retrospectively. We are currently evaluating the impact of ASU 2015-05 on our consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, or ASU No. 2014-09, which states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this, an entity will need to identify the contract with a customer; identify the separate performance obligations in the contract; determine the transaction price; allocate the transaction price to the separate performance obligations in the contract; and recognize revenue when (or as) the entity satisfies each performance obligation. In August 2015, the FASB issued ASU No. 2015-14, “Revenue from Contracts with Customers: Deferral of the Effective Date”, which deferred by one year the effective date of ASU No. 2014-09 which will now be effective for us beginning January 1, 2018 and can be adopted on a full retrospective basis or on a modified retrospective basis. We are currently assessing our approach to the adoption of this standard and the potential impact on our results of operations and financial position.

The Company and Summary of Si20

The Company and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basic and Diluted Net Income per Ordinary Share Computation	Basic and diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share were computed as follows (in thousands, except per share amounts): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Numerator: Net income (loss) attributable to Jazz Pharmaceuticals plc $ 87,960 $ 25,766 $ 246,774 $ (23,225 ) Denominator: Weighted-average ordinary shares used in per share calculation - basic 61,435 60,305 61,145 59,457 Dilutive effect of employee equity incentive and purchase plans 1,719 2,288 1,927 — Dilutive effect of warrants — 87 — — Weighted-average ordinary shares used in per share calculation - diluted 63,154 62,680 63,072 59,457 Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share: Basic $ 1.43 $ 0.43 $ 4.04 $ (0.39 ) Diluted $ 1.39 $ 0.41 $ 3.91 $ (0.39 )
Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share	The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 1.875% exchangeable senior notes due 2021 2,878 1,502 2,878 506 Options to purchase ordinary shares and RSUs 1,644 883 1,517 5,475 Warrants to purchase ordinary shares — — — 618 Ordinary shares under ESPP — — — 130

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents	Cash and cash equivalents consisted of the following (in thousands): September 30, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cash and Cash Equivalents Cash $ 193,256 $ — $ — $ 193,256 $ 193,256 Time deposits 805,603 — — 805,603 805,603 Totals $ 998,859 $ — $ — $ 998,859 $ 998,859 December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cash and Cash Equivalents Cash $ 338,262 $ — $ — $ 338,262 $ 338,262 Time deposits 345,780 — — 345,780 345,780 Totals $ 684,042 $ — $ — $ 684,042 $ 684,042
Available-for-Sale Securities and Other Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes, by major security type, our available-for-sale securities as of September 30, 2015 and December 31, 2014 that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands): September 30, 2015 December 31, 2014 Significant Other Observable Inputs (Level 2) Total Significant Total Time deposits $ 805,603 $ 805,603 $ 345,780 $ 345,780

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consisted of the following (in thousands): September 30, December 31, Raw materials $ 3,437 $ 3,570 Work in process 12,587 9,870 Finished goods 13,994 16,597 Total inventories $ 30,018 $ 30,037

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Gross Carrying Amount of Goodwill	The gross carrying amount of goodwill was as follows (in thousands): Balance at December 31, 2014 $ 702,713 Foreign exchange (33,684 ) Balance at September 30, 2015 $ 669,029
Gross Carrying Amounts and Net Book Values of Intangible Assets	The gross carrying amounts and net book values of our intangible assets were as follows (in thousands): September 30, 2015 December 31, 2014 Remaining Gross Accumulated Net Book Gross Accumulated Net Book Acquired developed technologies 12.2 $ 1,350,676 $ (305,982 ) $ 1,044,694 $ 1,450,606 $ (259,889 ) $ 1,190,717 Manufacturing contracts 2.3 12,037 (5,088 ) 6,949 13,012 (3,060 ) 9,952 Trademarks — 2,891 (2,891 ) — 2,914 (2,896 ) 18 Total finite-lived intangible assets 1,365,604 (313,961 ) 1,051,643 1,466,532 (265,845 ) 1,200,687 Acquired IPR&D assets 219,134 — 219,134 236,748 — 236,748 Total intangible assets $ 1,584,738 $ (313,961 ) $ 1,270,777 $ 1,703,280 $ (265,845 ) $ 1,437,435
Estimated Future Amortization Costs	Based on finite-lived intangible assets recorded as of September 30, 2015 , and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands): Year Ending December 31, Estimated Amortization Expense 2015 (remainder) $ 24,172 2016 92,510 2017 92,510 2018 89,623 2019 89,399 Thereafter 663,429 Total $ 1,051,643

Certain Balance Sheet Items (Ta

Certain Balance Sheet Items (Tables)	9 Months Ended
	Sep. 30, 2015
Certain Balance Sheet Items [Abstract]
Property and Equipment	Property and equipment consisted of the following (in thousands): September 30, December 31, Construction-in-progress $ 61,061 $ 37,145 Computer software 14,050 10,634 Computer equipment 11,266 7,670 Leasehold improvements 8,782 7,931 Machinery and equipment 5,862 6,408 Furniture and fixtures 2,339 2,220 Land and buildings 1,775 1,547 Subtotal 105,135 73,555 Less accumulated depreciation and amortization (21,683 ) (15,192 ) Property and equipment, net $ 83,452 $ 58,363
Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): September 30, December 31, Rebates and other sales deductions $ 63,676 $ 51,899 Employee compensation and benefits 33,893 46,143 Accrued milestone payment 25,000 — Sales returns reserve 7,757 14,039 Royalties 5,340 7,964 Professional fees 3,808 3,295 Accrued interest 1,927 10,327 Accrued construction-in-progress 1,690 4,931 Other 23,284 25,493 Total accrued liabilities $ 166,375 $ 164,091

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The following table summarizes the carrying amount of our indebtedness (in thousands): September 30, December 31, 1.875% exchangeable senior notes due 2021 $ 575,000 $ 575,000 Unamortized discount on 1.875% exchangeable senior notes due 2021 (113,108 ) (124,735 ) 1.875% exchangeable senior notes due 2021, net 461,892 450,265 Term loans 747,250 890,479 Borrowings under revolving credit facility 80,000 — Other borrowings 550 1,684 Total debt 1,289,692 1,342,428 Less current portion 117,589 9,428 Total long-term debt $ 1,172,103 $ 1,333,000
Schedule of Maturities of Long-Term Debt	Scheduled maturities with respect to our long-term debt are as follows (in thousands): Year Ending December 31, Scheduled Long-Term Debt Maturities 2015 (remainder) $ 9,397 2016 37,590 2017 42,280 2018 61,037 2019 79,792 Thereafter 1,175,454 Total $ 1,405,550

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments under Noncancelable Operating Leases	Future minimum lease payments under our noncancelable operating leases as of September 30, 2015 were as follows (in thousands): Year Ending December 31, Lease Payments 2015 (remainder) $ 2,874 2016 11,683 2017 12,556 2018 8,054 2019 7,197 Thereafter 73,296 Total $ 115,660

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Summary of stockholders equity	The following tables present a reconciliation of our beginning and ending balances in shareholders’ equity for the nine months ended September 30, 2015 and 2014, respectively (in thousands): Attributable to: Jazz Pharmaceuticals plc Noncontrolling interests Total Shareholders' Equity Shareholders' equity at January 1, 2015 $ 1,371,144 $ 64 $ 1,371,208 Acquisition of noncontrolling interests (5 ) (55 ) (60 ) Issuance of ordinary shares in conjunction with employee equity incentive and purchase plans 34,025 — 34,025 Employee withholding taxes related to share-based awards (25,402 ) — (25,402 ) Share-based compensation 67,729 — 67,729 Tax benefit from employee share options (320 ) — (320 ) Shares repurchased (21,302 ) — (21,302 ) Other comprehensive income (loss) (109,180 ) 6 (109,174 ) Net income (loss) 246,774 (1 ) 246,773 Shareholders' equity at September 30, 2015 $ 1,563,463 $ 14 $ 1,563,477 Attributable to: Jazz Pharmaceuticals plc Noncontrolling interests Total Shareholders' Equity Shareholders' equity at January 1, 2014 $ 1,295,534 $ — $ 1,295,534 Noncontrolling interests from the Gentium Acquisition — 136,578 136,578 Acquisition of noncontrolling interests (1,529 ) (135,421 ) (136,950 ) Issuance of 1.875% exchangeable senior notes due 2021 126,862 — 126,862 Issuance of ordinary shares in conjunction with employee equity incentive and purchase plans and warrant exercises 48,452 — 48,452 Employee withholding taxes related to share-based awards (17,306 ) — (17,306 ) Share-based compensation 50,919 — 50,919 Tax benefit from employee share options 4,075 — 4,075 Shares repurchased (29,973 ) (29,973 ) Other comprehensive loss (113,286 ) (7 ) (113,293 ) Net loss (23,225 ) (1,060 ) (24,285 ) Shareholders' equity at September 30, 2014 $ 1,340,523 $ 90 $ 1,340,613
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss attributable to Jazz Pharmaceuticals plc as of September 30, 2015 and December 31, 2014 were as follows (in thousands): Foreign Total Balance at December 31, 2014 $ (122,097 ) $ (122,097 ) Other comprehensive loss (109,180 ) (109,180 ) Balance at September 30, 2015 $ (231,277 ) $ (231,277 )

Segment and Other Information (

Segment and Other Information (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Summary of Total Revenues	The following table presents a summary of total revenues (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Xyrem ® (sodium oxybate) oral solution $ 242,899 $ 204,337 $ 703,435 $ 556,081 Erwinaze ® /Erwinase ® (asparaginase Erwinia chrysanthemi ) 56,317 52,121 152,821 146,910 Defitelio ® (defibrotide)/defibrotide 19,639 18,892 52,259 51,345 Prialt ® (ziconotide) intrathecal infusion 6,042 6,282 19,944 16,422 Psychiatry 9,910 10,833 28,375 32,431 Other 3,947 11,942 21,061 35,304 Product sales, net 338,754 304,407 977,895 838,493 Royalties and contract revenues 2,118 2,177 6,027 6,240 Total revenues $ 340,872 $ 306,584 $ 983,922 $ 844,733
Summary of Total Revenues Attributed to Geographic Sources	The following table presents a summary of total revenues attributed to geographic sources (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 United States $ 305,585 $ 264,719 $ 877,397 $ 727,200 Europe 26,076 32,578 82,837 87,608 All other 9,211 9,287 23,688 29,925 Total revenues $ 340,872 $ 306,584 $ 983,922 $ 844,733
Summary of Revenues from Customers Representing More Than 10% of Total Revenues	The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Express Scripts 71 % 67 % 71 % 66 % McKesson 14 % 1 % 5 % 5 % Accredo Health Group, Inc. — % 14 % 8 % 14 %
Total Long-Lived Assets by Location	The following table presents total long-lived assets, consisting of property and equipment, by location (in thousands): September 30, December 31, Ireland $ 60,447 $ 37,775 United States 12,255 9,795 Italy 8,424 8,462 Other 2,326 2,331 Total long-lived assets $ 83,452 $ 58,363

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation Expense	Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Selling, general and administrative $ 19,542 $ 14,834 $ 54,843 $ 40,051 Research and development 2,786 3,177 10,137 8,862 Cost of product sales 786 240 2,253 1,705 Total share-based compensation expense, pre-tax 23,114 18,251 67,233 50,618 Tax benefit from share-based compensation expense (6,658 ) (5,469 ) (19,722 ) (15,171 ) Total share-based compensation expense, net of tax $ 16,456 $ 12,782 $ 47,511 $ 35,447
Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model which was Used to Estimate Grant Date Fair Value per Share	The table below shows the number of shares underlying options granted to purchase our ordinary shares, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Shares underlying options granted (in thousands) 106 135 1,056 942 Grant date fair value $ 60.34 $ 51.73 $ 57.85 $ 60.40 Black-Scholes option pricing model assumption information: Volatility 40 % 42 % 39 % 45 % Expected term (years) 4.2 4.3 4.2 4.3 Range of risk-free rates 1.3-1.4% 1.3-1.4% 1.1-1.4% 1.1-1.4% Expected dividend yield — % — % — % — %
Schedule of Restricted Stock Unit activity	The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted: Three Months Ended Nine Months Ended 2015 2014 2015 2014 RSUs granted (in thousands) 40 68 406 459 Grant date fair value $ 179.10 $ 145.58 $ 175.22 $ 160.00

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	The following table summarizes the amounts related to restructuring through September 30, 2015 (in thousands): Termination Benefits Facility Closure Costs Total Balance at December 31, 2014 $ 1,823 $ 118 $ 1,941 Costs incurred during the period 381 172 553 Cash payments (2,204 ) (290 ) (2,494 ) Balance at September 30, 2015 $ — $ — $ —

The Company and Summary of Si31

The Company and Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended			3 Months Ended		9 Months Ended
	Oct. 31, 2015applicant	Jan. 31, 2015patent	Jan. 31, 2014applicant	Sep. 30, 2015USD ($)Customerapplication$ / shares	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)sharesCustomerapplication$ / shares	Sep. 30, 2014USD ($)	Dec. 31, 2014Customer
Summary Of Significant Accounting Policies [Line Items]
Product sales, net				$ 338,754	$ 304,407	$ 977,895	$ 838,493
Number of customers with significant accounts receivable | Customer				5		5		5
Percentage of gross accounts receivable				88.00%		88.00%		86.00%
Convertible Debt [Member]
Summary Of Significant Accounting Policies [Line Items]
Interest rate				1.875%	1.875%	1.875%	1.875%	1.875%
Number of shares issuable from exchangeable senior notes | shares						2.9
Debt conversion price (in dollars per share) | $ / shares				$ 199.77		$ 199.77
Express Scripts [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable				67.00%		67.00%		66.00%
McKesson [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable				10.00%		10.00%
Idis Limited [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable								11.00%
Xyrem [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales, net				$ 242,899	$ 204,337	$ 703,435	$ 556,081
Number of ANDAs filed by third parties | application				7		7
Number of patents covering the distribution system | patent		6
Number of additional ANDA applicants | applicant			3
Xyrem [Member] | Sales Revenue, Product Line [Member] | Product Concentration Risk [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of product sales, net				71.70%		71.90%
Erwinaze And Erwinase [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales, net				$ 56,317	$ 52,121	$ 152,821	$ 146,910
Erwinaze And Erwinase [Member] | Sales Revenue, Product Line [Member] | Product Concentration Risk [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of product sales, net				16.60%		15.60%
Subsequent Event [Member] | Xyrem [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of additional ANDA applicants | applicant	7

The Company and Summary of Si32

The Company and Summary of Significant Accounting Policies - Basic and Diluted Net Income (Loss) per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator:
Net income (loss) attributable to Jazz Pharmaceuticals plc	$ 87,960	$ 25,766	$ 246,774	$ (23,225)
Denominator:
Weighted-average ordinary shares used in per share calculation - basic (in shares)	61,435	60,305	61,145	59,457
Dilutive effect of employee equity incentive and purchase plans (in shares)	1,719	2,288	1,927	0
Dilutive effect of warrants (in shares)	0	87	0	0
Weighted-average ordinary shares - diluted (in shares)	63,154	62,680	63,072	59,457
Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
Basic net income (in dollars per share)	$ 1.43	$ 0.43	$ 4.04	$ (0.39)
Diluted net income (in dollars per share)	$ 1.39	$ 0.41	$ 3.91	$ (0.39)

The Company and Summary of Si33

The Company and Summary of Significant Accounting Policies - Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares	2,878	1,502	2,878	506
Equity Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares	1,644	883	1,517	5,475
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares	0	0	0	618
Ordinary shares under ESPP [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares	0	0	0	130
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest rate	1.875%	1.875%	1.875%	1.875%	1.875%

Disposition - Additional Inform

Disposition - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net proceeds from sale of business		$ 33,703	$ 0
Certain EUSA Products [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration	$ 34,000
Net proceeds from sale of business	$ 33,000
Certain EUSA Products [Member] | Selling, general and administrative [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on disposal		$ 200

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Cash and cash equivalents [Line Items]
Amortized Cost	$ 998,859	$ 684,042
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	998,859	684,042
Cash and cash equivalents	998,859	684,042	$ 575,040	$ 636,504
Cash [Member]
Cash and cash equivalents [Line Items]
Amortized Cost	193,256	338,262
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	193,256	338,262
Cash and cash equivalents	193,256	338,262
Time deposits [Member]
Cash and cash equivalents [Line Items]
Amortized Cost	805,603	345,780
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	805,603	345,780
Cash and cash equivalents	$ 805,603	$ 345,780

Fair Value Measurement - Availa

Fair Value Measurement - Available-For-Sale Investments Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Estimated Fair Value	$ 998,859	$ 684,042
Time deposits [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Estimated Fair Value	805,603	345,780
Fair Value, Measurements, Recurring [Member] | Time deposits [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Estimated Fair Value	805,603	345,780
Fair Value, Measurements, Recurring [Member] | Time deposits [Member] | Fair Value, Inputs, Level 2 [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Estimated Fair Value	$ 805,603	$ 345,780

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value Measurements [Line Items]
Assets held for sale	$ 0	$ 32,833
Convertible Debt [Member]
Fair Value Measurements [Line Items]
Fair value of exchangeable senior notes	$ 587,000

Inventories - Components of Inv

Inventories - Components of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 3,437	$ 3,570
Work in process	12,587	9,870
Finished goods	13,994	16,597
Total inventories	$ 30,018	$ 30,037

Goodwill and Intangible Asset39

Goodwill and Intangible Assets - Additional Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill [Roll Forward]
Goodwill, beginning of period	$ 702,713
Foreign exchange	(33,684)
Goodwill, end of period	$ 669,029

Goodwill and Intangible Asset40

Goodwill and Intangible Assets - Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount - Finite-Lived Intangible Assets	$ 1,365,604	$ 1,466,532
Accumulated Amortization - Finite-Lived Intangible Assets	(313,961)	(265,845)
Total	1,051,643	1,200,687
Gross Carrying Amount - Total Intangible Assets	1,584,738	1,703,280
Net Book Value - Total Intangible Assets	1,270,777	1,437,435
Acquired IPR&D assets [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
In-process research and development	$ 219,134	236,748
Acquired developed technologies [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	12 years 2 months
Gross Carrying Amount - Finite-Lived Intangible Assets	$ 1,350,676	1,450,606
Accumulated Amortization - Finite-Lived Intangible Assets	(305,982)	(259,889)
Total	$ 1,044,694	1,190,717
Manufacturing Contracts [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	2 years 4 months
Gross Carrying Amount - Finite-Lived Intangible Assets	$ 12,037	13,012
Accumulated Amortization - Finite-Lived Intangible Assets	(5,088)	(3,060)
Total	$ 6,949	9,952
Trademarks [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	0 years
Gross Carrying Amount - Finite-Lived Intangible Assets	$ 2,891	2,914
Accumulated Amortization - Finite-Lived Intangible Assets	(2,891)	(2,896)
Total	$ 0	$ 18

Goodwill and Intangible Asset41

Goodwill and Intangible Assets - Estimated Future Amortization Costs (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Estimated Amortization Expense
2015 (remainder)	$ 24,172
2,016	92,510
2,017	92,510
2,018	89,623
2,019	89,399
Thereafter	663,429
Total	$ 1,051,643	$ 1,200,687

Certain Balance Sheet Items - P

Certain Balance Sheet Items - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Certain Balance Sheet Items [Abstract]
Construction-in-progress	$ 61,061	$ 37,145
Computer software	14,050	10,634
Computer equipment	11,266	7,670
Leasehold improvements	8,782	7,931
Machinery and equipment	5,862	6,408
Furniture and fixtures	2,339	2,220
Land and buildings	1,775	1,547
Subtotal	105,135	73,555
Less accumulated depreciation and amortization	(21,683)	(15,192)
Property and equipment, net	$ 83,452	$ 58,363

Certain Balance Sheet Items - A

Certain Balance Sheet Items - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Certain Balance Sheet Items [Abstract]
Rebates and other sales deductions	$ 63,676	$ 51,899
Employee compensation and benefits	33,893	46,143
Accrued milestone payment	25,000	0
Sales returns reserve	7,757	14,039
Royalties	5,340	7,964
Professional fees	3,808	3,295
Accrued interest	1,927	10,327
Accrued construction-in-progress	1,690	4,931
Other	23,284	25,493
Total accrued liabilities	$ 166,375	$ 164,091

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014
Debt Instrument [Line Items]
Principal amount	$ 1,405,550
Total debt	1,289,692	$ 1,342,428
Less current portion	117,589	9,428
Total long-term debt	1,172,103	1,333,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Total debt	$ 80,000	$ 0
Convertible Debt 2021 Notes [Member]
Debt Instrument [Line Items]
Interest rate	1.875%	1.875%	1.875%
Principal amount	$ 575,000	$ 575,000
Unamortized discount	(113,108)	(124,735)
Total debt	461,892	450,265
Term Loans [Member]
Debt Instrument [Line Items]
Total debt	747,250	890,479
Other borrowings [Member]
Debt Instrument [Line Items]
Total debt	$ 550	$ 1,684

Debt - Schedule of Maturities (

Debt - Schedule of Maturities (Details) $ in Thousands	Sep. 30, 2015USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2015 (remainder)	$ 9,397
2,016	37,590
2,017	42,280
2,018	61,037
2,019	79,792
Thereafter	1,175,454
Total debt	$ 1,405,550

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)	Jun. 18, 2015	Jun. 17, 2015	Oct. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Loss on extinguishment and modification of debt				$ 0	$ 0	$ 16,815,000	$ 0
June 2015 Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity	$ 750,000,000
Credit facility, amount outstanding	$ 160,000,000			80,000,000		80,000,000
Maturity date	Jun. 18, 2020
Letters of credit, amount outstanding				$ 1,100,000		$ 1,100,000
Interest rate				1.96%		1.96%
June 2015 Credit Agreement [Member] | Revolving Credit Facility [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Repayment of outstanding balance			$ 80,000,000
June 2015 Credit Agreement [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Commitment fee (percentage)	0.25%
June 2015 Credit Agreement [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Commitment fee (percentage)	0.35%
Term Loans [Member] | June 2015 Credit Agreement [Member]
Debt Instrument [Line Items]
Principal amount	$ 750,000,000
Maturity date	Jun. 18, 2020
Interest rate				2.09%
Effective interest rate				2.38%		2.38%
Principal repayment in year one and two (percent)	5.00%
Principal repayment in year three (percent)	7.50%
Principal repayment in year four (percent)	10.00%
Principal repayment in year five (percent)	12.50%
Term Loans [Member] | June 2015 Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Variable interest rate	1.50%
Term Loans [Member] | June 2015 Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Variable interest rate	2.25%
Term Loans [Member] | June 2015 Credit Agreement [Member] | Prime Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Variable interest rate	0.50%
Term Loans [Member] | June 2015 Credit Agreement [Member] | Prime Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Variable interest rate	1.25%
Term Loans [Member] | 2012 Credit Agreement [Member]
Debt Instrument [Line Items]
Gross amount of debt extinguished		$ 893,100,000
Loss on extinguishment and modification of debt						$ 16,815,000
Unamortized deferred financing costs and unamortized discount						16,000,000
Debt modification costs						800,000
Convertible Debt 2021 Notes [Member]
Debt Instrument [Line Items]
Carrying value of the equity component				$ 126,900,000		$ 126,900,000

Commitments and Contingencies -

Commitments and Contingencies - Future Minimum Lease Payments under Noncancelable Operating Leases (Details) $ in Thousands	Sep. 30, 2015USD ($)
Lease Payments
2015 (remainder)	$ 2,874
2,016	11,683
2,017	12,556
2,018	8,054
2,019	7,197
Thereafter	73,296
Total	$ 115,660

Commitments and Contingencies48

Commitments and Contingencies - Additional Information (Details)

Sep. 02, 2015patent

Jul. 23, 2015patent

Jul. 17, 2015patent

Jun. 26, 2015patent

Jun. 08, 2015patent

Feb. 20, 2015patent

Jan. 08, 2015patent

Dec. 11, 2014patent

Oct. 02, 2014patent

Jul. 15, 2014patent

May. 20, 2014patent

Dec. 27, 2013patent

Nov. 21, 2013

Jan. 18, 2013patent

Dec. 10, 2012

Nov. 22, 2010

Oct. 18, 2010patent

Oct. 31, 2015patent

Apr. 30, 2015USD ($)renewal_term

Jan. 31, 2015USD ($)patentrenewal_term

Sep. 30, 2015USD ($)application

Aug. 31, 2014patent

Sep. 30, 2015USD ($)productapplication

Jul. 23, 2010patent

Dec. 05, 2012patent

Dec. 31, 2014USD ($)

Oct. 19, 2011USD ($)

Nov. 25, 2008lawsuit

Commitments and Contingencies Disclosure [Line Items]

Total future lease payments

$ 115,660,000

$ 115,660,000

Construction-in-progress

61,061,000

61,061,000

$ 37,145,000

Other non-current liabilities

59,666,000

59,666,000

$ 38,393,000

Noncancelable purchase commitments, due within one year

$ 25,600,000

$ 25,600,000

Number of radiopharmaceutical products | product

2

Xyrem [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of ANDAs outstanding | application

7

7

Pending Litigation [Member] | Xyrem [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of patents named in CBM petitions | patent

6

6

Pending Litigation [Member] | Xyrem ANDA Matters [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of patents allegedly infringed upon | patent

18

16

17

2

15

3

3

15

2

14

4

13

9

5

10

Court ordered stay period

30 months

30 months

30 months

Pending Litigation [Member] | FazaClo ANDA Matters [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of ANDAs filed by 3rd parties | patent

3

Number of ANDAs outstanding | lawsuit

2

Pending Litigation [Member] | FazaClo [Member]

Commitments and Contingencies Disclosure [Line Items]

Amounts sought in alleged breach of contractual obligations - minimum

$ 10,500,000

Amounts sought in alleged breach of contractual obligations - additional

$ 25,000,000

Palo Alto [Member] | Building [Member]

Commitments and Contingencies Disclosure [Line Items]

Operating lease, term (in years)

12 years

Number of renewal option terms | renewal_term

2

2

Operating lease, extended term option (in years)

1 year

5 years

Total future lease payments

$ 10,000,000

$ 88,000,000

Rent expense

$ 500,000

$ 1,300,000

Palo Alto [Member] | Building [Member] | Property and Equipment, Net [Member]

Commitments and Contingencies Disclosure [Line Items]

Construction-in-progress

2,700,000

2,700,000

Palo Alto [Member] | Building [Member] | Other Non-Current Liabilities [Member]

Commitments and Contingencies Disclosure [Line Items]

Other non-current liabilities

$ 2,700,000

$ 2,700,000

Subsequent Event [Member] | Pending Litigation [Member] | Xyrem [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of patents named in CBM petitions | patent

1

Shareholders' Equity - Share Re

Shareholders' Equity - Share Repurchase Programs (Details) - Ordinary Options [Member] - USD ($) $ / shares in Units, shares in Millions	9 Months Ended
	Sep. 30, 2015	Nov. 05, 2015	May. 31, 2013
Stock Activity [Line Items]
Total amount authorized for repurchase of shares under share repurchase program			$ 200,000,000
Shares repurchased	$ 21,300,000
Shares repurchased (in shares)	0.1
Average price of shares repurchased (in dollars per share)	$ 172.43
Subsequent Event [Member]
Stock Activity [Line Items]
Total amount authorized for repurchase of shares under share repurchase program		$ 300,000,000

Shareholders' Equity - Sharehol

Shareholders' Equity - Shareholders Equity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders equity, beginning of period			$ 1,371,208	$ 1,295,534
Noncontrolling interests from the Gentium Acquisition				136,578
Acquisition of noncontrolling interests			(60)	(136,950)
Issuance of 1.875% exchangeable senior notes due 2021				126,862
Issuance of ordinary shares in conjunction with employee equity incentive and purchase plans and warrant exercises			34,025	48,452
Employee withholding taxes related to share-based awards			(25,402)	(17,306)
Share-based compensation			67,729	50,919
Tax benefit from employee share options			(320)	4,075
Shares repurchased			(21,302)	(29,973)
Other comprehensive income (loss)			(109,174)	(113,293)
Net income (loss)	$ 87,960	$ 25,768	246,773	(24,285)
Shareholders equity, end of period	$ 1,563,477	$ 1,340,613	$ 1,563,477	$ 1,340,613
Convertible Debt [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest rate	1.875%	1.875%	1.875%	1.875%	1.875%
Parent [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders equity, beginning of period			$ 1,371,144	$ 1,295,534
Noncontrolling interests from the Gentium Acquisition				0
Acquisition of noncontrolling interests			(5)	(1,529)
Issuance of 1.875% exchangeable senior notes due 2021				126,862
Issuance of ordinary shares in conjunction with employee equity incentive and purchase plans and warrant exercises			34,025	48,452
Employee withholding taxes related to share-based awards			(25,402)	(17,306)
Share-based compensation			67,729	50,919
Tax benefit from employee share options			(320)	4,075
Shares repurchased			(21,302)	(29,973)
Other comprehensive income (loss)			(109,180)	(113,286)
Net income (loss)			246,774	(23,225)
Shareholders equity, end of period	$ 1,563,463	$ 1,340,523	1,563,463	1,340,523
Noncontrolling Interest [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders equity, beginning of period			64	0
Noncontrolling interests from the Gentium Acquisition				136,578
Acquisition of noncontrolling interests			(55)	(135,421)
Other comprehensive income (loss)			6	(7)
Net income (loss)			(1)	(1,060)
Shareholders equity, end of period	$ 14	$ 90	$ 14	$ 90

Shareholders' Equity - Componen

Shareholders' Equity - Component of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2014			$ (122,097)
Other comprehensive loss	$ 16,779	$ (117,089)	(109,174)	$ (113,293)
Balance at September 30, 2015	(231,277)		(231,277)
Foreign Currency Translation Adjustments [Member]
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2014			(122,097)
Other comprehensive loss			(109,180)
Balance at September 30, 2015	(231,277)		(231,277)
Parent [Member]
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2014			(122,097)
Other comprehensive loss			(109,180)
Balance at September 30, 2015	$ (231,277)		$ (231,277)

Segment and Other Information -

Segment and Other Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2015Segment
Segment Reporting [Abstract]
Number of operating business segment	1

Segment and Other Information53

Segment and Other Information - Summary of Total Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue from External Customer [Line Items]
Product sales, net	$ 338,754	$ 304,407	$ 977,895	$ 838,493
Royalties and contract revenues	2,118	2,177	6,027	6,240
Total revenues	340,872	306,584	983,922	844,733
Xyrem [Member]
Revenue from External Customer [Line Items]
Product sales, net	242,899	204,337	703,435	556,081
Erwinaze And Erwinase [Member]
Revenue from External Customer [Line Items]
Product sales, net	56,317	52,121	152,821	146,910
Defitelio [Member]
Revenue from External Customer [Line Items]
Product sales, net	19,639	18,892	52,259	51,345
Prialt [Member]
Revenue from External Customer [Line Items]
Product sales, net	6,042	6,282	19,944	16,422
Psychiatry [Member]
Revenue from External Customer [Line Items]
Product sales, net	9,910	10,833	28,375	32,431
Other [Member]
Revenue from External Customer [Line Items]
Product sales, net	$ 3,947	$ 11,942	$ 21,061	$ 35,304

Segment and Other Information54

Segment and Other Information - Summary of Total Revenues Attributed to Geographic Sources (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 340,872	$ 306,584	$ 983,922	$ 844,733
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	305,585	264,719	877,397	727,200
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	26,076	32,578	82,837	87,608
All Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 9,211	$ 9,287	$ 23,688	$ 29,925

Segment and Other Information55

Segment and Other Information - Summary of Revenues from Customers Representing at Least 10% of Total Revenues (Details) - Sales Revenue, Goods, Net [Member] - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Express Scripts [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues	71.00%	67.00%	71.00%	66.00%
McKesson [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues	14.00%	1.00%	5.00%	5.00%
Accredo Health Group, Inc. [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues	0.00%	14.00%	8.00%	14.00%

Segment and Other Information56

Segment and Other Information - Total Long-Lived Assets by Location (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment, net	$ 83,452	$ 58,363
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment, net	60,447	37,775
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment, net	12,255	9,795
Italy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment, net	8,424	8,462
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment, net	$ 2,326	$ 2,331

Share-Based Compensation - Shar

Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 23,114	$ 18,251	$ 67,233	$ 50,618
Tax benefit from share-based compensation expense	(6,658)	(5,469)	(19,722)	(15,171)
Total share-based compensation expense, net of tax	16,456	12,782	47,511	35,447
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	19,542	14,834	54,843	40,051
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	2,786	3,177	10,137	8,862
Cost of product sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 786	$ 240	$ 2,253	$ 1,705

Share-Based Compensation - Weig

Share-Based Compensation - Weighted-Average Assumptions and Resulting Grant Date Fair Value (Details) - Employee Stock Option [Member] - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Schedule of Weighted Average Assumptions for Fair Values of Stock Options[Line Items]
Shares underlying options granted (in shares)	106	135	1,056	942
Weighted-average grant date fair value (in dollars per share)	$ 60.34	$ 51.73	$ 57.85	$ 60.40
Weighted-average volatility	40.00%	42.00%	39.00%	45.00%
Weighted-average expected term (years)	4 years 2 months 24 days	4 years 3 months 24 days	4 years 2 months 24 days	4 years 3 months 24 days
Range of risk-free rates, minimum	1.30%	1.30%	1.10%	1.10%
Range of risk-free rates, maximum	1.40%	1.40%	1.40%	1.40%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Share-Based Compensation - Rest

Share-Based Compensation - Restricted Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Units granted	40	68	406	459
Weighted average grand date fair value (in dollars per share)	$ 179.10	$ 145.58	$ 175.22	$ 160

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Unrecognized compensation cost related to unvested stock option and RSUs	$ 93.8
Weighted-average period expected to be recognized	2 years 3 months 24 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested stock option and RSUs	$ 83.4
Weighted-average period expected to be recognized	2 years 6 months 1 day

Restructuring - Restructuring A

Restructuring - Restructuring Activities (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Restructuring Reserve [Roll Forward]
Cash payments	$ (2,494)
One-time Termination Benefits [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period		$ 2,200
Cash payments	(2,204)
Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period		300
Cash payments	(290)
Selling, general and administrative [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period	553
Selling, general and administrative [Member] | One-time Termination Benefits [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period	381
Selling, general and administrative [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period	172
Accrued Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning of period	1,941
Balance, end of period	0	0
Accrued Liabilities [Member] | One-time Termination Benefits [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning of period	1,823
Balance, end of period	0	0
Accrued Liabilities [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning of period	118
Balance, end of period	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Taxes [Line Items]
Income tax provision	$ 29,945	$ 24,221	$ 92,651	$ 60,598
Effective income tax rate, percentage	25.40%		27.30%
Acquired in-process research and development	$ 0	$ 75,000	$ 0	$ 202,000
Non-Taxable Jurisdiction [Member]
Income Taxes [Line Items]
Modified effective income tax rate, percentage		19.40%		25.40%
Ireland [Member]
Income Taxes [Line Items]
Effective statutory income tax rate, percentage	12.50%		12.50%